{
  "../data/ABEONA-THERAPEUTICS-INC/1996/10-Q/0000318306-96-000002/EX-10.18.txt": {
    "contract": {
      "title": "1995 Stock Option Plan (Unknown)",
      "contract_type": "License Agreement",
      "summary": "This is a stock option plan for Access Pharmaceuticals, Inc., as amended on 1996-03-28. It outlines the terms and conditions for granting stock options to employees, consultants, and directors.",
      "execution_date": "1995-09-14",
      "effective_date": "1995-09-14",
      "expiration_date": "2005-09-14",
      "licensor": {
        "name": "Access Pharmaceuticals, Inc.",
        "address": null,
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "low sale prices of Common Stock on the stock exchange or market on which Common Stock is primarily traded on the date as of which such value is being determined or",
        "address": null,
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "agreement_grants": "The Plan allows for the grant or sale of Options or SARs to employees, consultants, and directors of the Company and its subsidiaries to encourage ownership of the Stock.",
      "exclusivity_grant_type": null,
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [],
      "licensed_territory": [],
      "contract_term": "fixed end date",
      "contract_term_details": "Options under the Plan may be granted on or after 1995-09-14 but not later than 2005-09-14.",
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": "non-transferable without agreement by licensor",
      "assignment_restrictions_details": "Options shall not be transferable, otherwise than by will or the laws of descent and distribution, and may be exercised during the life of the Optionee only by the Optionee",
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [],
      "governing_law": null,
      "jurisdiction": null,
      "termination_rights": null,
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/1996/10-Q/0000318306-96-000002/EX-10.18.txt",
      "year": "1996",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:56:00.568067",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/1996/10-Q/0000318306-96-000003/EX-10.19.txt": {
    "contract": {
      "title": "LEASE AGREEMENT (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between Pollock Realty Corporation (licensor) and Access Pharmaceuticals, Inc. (licensee). Grant type: Nonexclusive. Upfront payment: $7,459.70. Territory: 1 region(s)",
      "execution_date": null,
      "effective_date": null,
      "expiration_date": null,
      "licensor": {
        "name": "Pollock Realty Corporation",
        "address": "2600 Stemmons Frwy Suite 176 Dallas, Texas 75207",
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "licensee": {
        "name": "Access Pharmaceuticals, Inc.",
        "address": null,
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "agreement_grants": "Landlord leases to Tenant, and Tenant takes from Landlord the approximately 9,088 square feet more particularly outlined on the floor plan, attached as Exhibit \"A-1\" (the \"Premises\"), which Premises are part of that approximately 39,733 square foot building (the \"Building\") which are part of that approximately 94,639 square foot project (the \"Project\") located on the real property situated within the County of Dallas, State of Texas, which real rights, privileges, easements, appurtenances, and amenities belonging to or in any way pertaining to the Premises, to have and to hold, subject to the terms, covenants and conditions in this Lease.",
      "exclusivity_grant_type": "Nonexclusive",
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [],
      "licensed_territory": [
        {
          "territory_name": "County of Dallas, State of Texas",
          "territory_type": null,
          "restrictions": null
        }
      ],
      "contract_term": "fixed end date",
      "contract_term_details": "The term of this Lease shall commence upon either (i) 1996-10-01, or (ii) if Landlord is required to construct improvements in the Premises pursuant to Paragraph 1.C. below, on the date of substantial completion of any such alterations or improvements to the Premises described in Paragraph 1.C. below (the \"Commencement Date\"). The term of this Lease shall end on the last day of the calendar month that is 74 full calendar months after the Commencement Date.",
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": 7459.7,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "Exhibit A-1",
          "type": null,
          "description": "Floor plan of the Premises",
          "reference_section": "1.A"
        },
        {
          "name": "Exhibit B",
          "type": null,
          "description": "Plans and specifications for improvements and alterations to be constructed and installed by Landlord",
          "reference_section": "1.C"
        }
      ],
      "governing_law": "Texas",
      "jurisdiction": null,
      "termination_rights": "Not specified",
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/1996/10-Q/0000318306-96-000003/EX-10.19.txt",
      "year": "1996",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:56:04.699777",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/1996/10-K/0000950146-96-000501/EX-10.16.txt": {
    "contract": {
      "title": "PATENT PURCHASE AGREEMENT (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between David F. Ranney (licensor) and ACCESS PHARMACEUTICALS, INC (licensee). Grant type: Nonexclusive. Licenses 7 patent(s). Upfront payment: $7,500.00. Executed: 1994-04-05",
      "execution_date": "1994-04-05",
      "effective_date": null,
      "expiration_date": null,
      "licensor": {
        "name": "David F. Ranney",
        "address": "3539 Courtdale Drive, Dallas, Texas 75234",
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "licensee": {
        "name": "ACCESS PHARMACEUTICALS, INC",
        "address": "2600 N. Stemmons Freeway, Suite 210, Dallas, Texas 75207",
        "entity_type": "corporation",
        "jurisdiction": "Texas",
        "contact_info": null
      },
      "agreement_grants": "Ranney sells, transfers, conveys, assigns, delivers and sets over to Access all of Ranney's right, title and interest in, to and under all of the patents and patent applications listed on Schedule A hereto and all divisions, continuations, continuations-in-part, re-issues and extensions thereof.",
      "exclusivity_grant_type": "Nonexclusive",
      "exclusivity_milestones": [],
      "right_to_sublicense": true,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": "inventions and technology covered by or relating to the Patents (i) for his own research, teaching and other  academic related purposes, and (ii) after Ranney is no longer a full-time employee of Access, for research and development of uses or implementations of the inventions and technology improvements related to or dependent on the Patents.",
      "licensed_patents": [
        {
          "patent_number": "4925678",
          "patent_title": null,
          "filing_date": null,
          "issue_date": null
        },
        {
          "patent_number": "607",
          "patent_title": null,
          "filing_date": null,
          "issue_date": null
        },
        {
          "patent_number": "035",
          "patent_title": null,
          "filing_date": null,
          "issue_date": null
        },
        {
          "patent_number": "5108759",
          "patent_title": null,
          "filing_date": null,
          "issue_date": null
        },
        {
          "patent_number": "5260050",
          "patent_title": null,
          "filing_date": null,
          "issue_date": null
        },
        {
          "patent_number": "628",
          "patent_title": null,
          "filing_date": null,
          "issue_date": null
        },
        {
          "patent_number": "5213788",
          "patent_title": null,
          "filing_date": null,
          "issue_date": null
        }
      ],
      "licensed_products": [],
      "licensed_territory": [],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": "Ranney retains the non-exclusive right to use the inventions and technology covered by or relating to the Patents (i) for his own research, teaching and other  academic related purposes, and (ii) after Ranney is no longer a full-time employee of Access, for research and development of uses or implementations of the inventions and technology improvements related to or dependent on the Patents.",
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": 7500.0,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": "Access shall allow Ranney and his agents, attorneys, and accountants full access at all reasonable times to inspect and make copies of or extracts from such books, records, invoices and documents as may be reasonably necessary for the purpose of verifying the amount of the Purchase Price to be paid pursuant to this Agreement.",
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": true,
      "confidential_materials": "confidential records of Access",
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "Exhibit AA",
          "type": null,
          "description": "form of an assignment",
          "reference_section": "1.1"
        }
      ],
      "governing_law": "Laws of the State of Texas",
      "jurisdiction": "Dallas",
      "termination_rights": "the existing Exclusive Technology Licensing Agreements between Access and Ranney, dated 1988-12-15 and 1989-02-28, respectively, and including the Addenda thereto, dated 1990-02-13 (collectively, the \"Licenses\"), shall terminate and be of no further effect, except that the provisions of the Licenses regarding indemnification and confidential information shall continue in full force and effect.",
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/1996/10-K/0000950146-96-000501/EX-10.16.txt",
      "year": "1996",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:56:09.127900",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/1996/10-K/0000950146-96-000501/EX-10.17.txt": {
    "contract": {
      "title": "FIRST AMENDMENT to PATENT PURCHASE AGREEMENT (Unknown)",
      "contract_type": "Patent Purchase Agreement",
      "summary": "License agreement between David F. Ranney (licensor) and ACCESS Pharmaceuticals, Inc. (licensee). Upfront payment: $7,500.00. Executed: 1996-01-23",
      "execution_date": "1996-01-23",
      "effective_date": null,
      "expiration_date": null,
      "licensor": {
        "name": "David F. Ranney",
        "address": null,
        "entity_type": "individual",
        "jurisdiction": null,
        "contact_info": null
      },
      "licensee": {
        "name": "ACCESS Pharmaceuticals, Inc.",
        "address": "formerly Chemex Pharmaceuticals, Inc.",
        "entity_type": "corporation",
        "jurisdiction": "Texas",
        "contact_info": null
      },
      "agreement_grants": "Patent Purchase Agreement and a Patent Assignment Agreement",
      "exclusivity_grant_type": null,
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [],
      "licensed_territory": [],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": 7500.0,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [],
      "governing_law": null,
      "jurisdiction": null,
      "termination_rights": null,
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/1996/10-K/0000950146-96-000501/EX-10.17.txt",
      "year": "1996",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:56:11.247985",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/1997/10-Q/0000318306-97-000010/EX-10.12.txt": {
    "contract": {
      "title": "LICENSE AGREEMENT BETWEEN THE DOW CHEMICAL COMPANY AND THE COMPANY DATED JUNE 30, 1997 (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between THE DOW CHEMICAL COMPANY (licensor) and Access Pharmaceuticals, Inc. (licensee). Grant type: Exclusive. Territory: 1 region(s). Executed: 1997-06-30",
      "execution_date": "1997-06-30",
      "effective_date": "1997-06-30",
      "expiration_date": null,
      "licensor": {
        "name": "THE DOW CHEMICAL COMPANY",
        "address": "2030 Dow Center, Midland, Michigan 48674, United States of America",
        "entity_type": "corporation",
        "jurisdiction": "State of Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "Access Pharmaceuticals, Inc.",
        "address": "2600 Stemmons Freeway, Suite 176, Dallas, TX 75207-2107",
        "entity_type": "corporation",
        "jurisdiction": "State of Delaware",
        "contact_info": null
      },
      "agreement_grants": "DOW grants to API: (a) an exclusive license to use the TECHNOLOGY to make, have made, use, develop, modify, sell and have sold PRODUCT in the TERRITORY in the FIELD, and an exclusive license under the PATENTS listed in Appendix A (as amended at the annual revision), to make, have made, use, develop, sell and have sold PRODUCT in the TERRITORY in the FIELD. This License shall be fully exclusive, to the exclusion of DOW and its AFFILIATES; and (b) a non-exclusive license to use the MANUFACTURE to make or have made AGENT in the TERRITORY, but only for use in PRODUCT in the FIELD in the TERRITORY, but subject to Article 2.5, and only for so long as this License is in effect.",
      "exclusivity_grant_type": "Exclusive",
      "exclusivity_milestones": [],
      "right_to_sublicense": true,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": "the use in humans of PRODUCT as magnetic resonance imaging (MRI) contrast agents, radiopharmaceutical diagnostic agents and radiopharmaceutical therapeutic agents; and expressly excludes any use specifically and primarily intended: (i) as a non-radiopharmaceutical diagnostic agent other than MRI; (ii) as a non-radiopharmaceutical therapeutic agent, including as a combination therapy; and (iii) as a veterinary agent.",
      "licensed_patents": [],
      "licensed_products": [],
      "licensed_territory": [
        {
          "territory_name": "the world",
          "territory_type": null,
          "restrictions": null
        }
      ],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": "DOW reserves the right to make, have made, and use AGENT or PRODUCT in the FIELD in the TERRITORY for the purposes of: (i) research requested by API during the RESEARCH TERM; and (ii) basic research and development of AGENT; and (iii) supply to API under such supply agreements as may be agreed upon in writing between the Parties; and (iv) publication of data on AGENT, after filing any appropriate patents, including MANUFACTURE.\nDOW reserves the right for DOW to proceed, solely at its option and expense, to research, develop, make, have made, use, sell ,have sold and license, in the TERRITORY outside the FIELD: (i) AGENT; and (ii) complexes of AGENT with any metal, including METAL ION.",
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": true,
      "confidential_materials": "any information of either Party regarding TECHNOLOGY, PATENTS, any samples of AGENT or PRODUCT, financial terms of this License, and business development plans for the PRODUCT, and does not include information excluded under Article 7.2.",
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [],
      "governing_law": null,
      "jurisdiction": null,
      "termination_rights": null,
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/1997/10-Q/0000318306-97-000010/EX-10.12.txt",
      "year": "1997",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:56:16.406957",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/1997/10-K/0000318306-97-000003/EX-10.19.txt": {
    "contract": {
      "title": "PLATINATE HPMA COPOLYMER ROYALTY AGREEMENT (Unknown)",
      "contract_type": "License Agreement",
      "summary": "This is a Platinate HPMA Copolymer Royalty Agreement between The London School of Pharmacy, University of London and Access Pharmaceuticals, Inc. dated November 19, 1996. It grants Access Pharmaceuticals exclusive rights to develop, manufacture, and sell products related to Cisplatin HPMA Copolymer technology worldwide, based on patents and know-how jointly owned by both parties. The agreement outlines terms for royalties, obligations, confidentiality, and termination.",
      "execution_date": "1996-11-19",
      "effective_date": "1996-11-19",
      "expiration_date": null,
      "licensor": {
        "name": "The School of Pharmacy, University of London",
        "address": "29/39 Brunswick Square, London, WC1N 1AX, England",
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "licensee": {
        "name": "Access Pharmaceuticals, Inc",
        "address": "2600 North Stemmons Freeway, S uite 176, Dallas, TX 75207-2107",
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "agreement_grants": "UNIVERSITY grants to ACCESS an exclusive right, with the right to sublicense, under the ACCESS and UNIVERSITY Patents and Know-How to develop, modify, have made, have used and have sold the Products in the Licensed Territory.",
      "exclusivity_grant_type": "Exclusive",
      "exclusivity_milestones": [],
      "right_to_sublicense": true,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": "development, modify, have made, have used and have sold the Products",
      "licensed_patents": [],
      "licensed_products": [
        {
          "product_name": "soluble synthetic HPMA polymer conjugate of Cisplatin and/or other platinum analogues",
          "description": "developed pursuant to the terms of the Agreement between the Parties dated 1996-11-19 and utilizing the ACCESS and UNIVERSITY Patent and Know-How",
          "category": null
        }
      ],
      "licensed_territory": [
        {
          "territory_name": "Worldwide",
          "territory_type": null,
          "restrictions": null
        }
      ],
      "contract_term": "variable end",
      "contract_term_details": "This Agreement shall commence upon the Effective Date and shall expire in each country of the Licensed Territory upon expiration of the last-to-expire ACCESS and UNIVERSITY Patents in such country of the Licensed Territory, as may be extended by the laws of such country in terms of Regulatory Market Exclusivity for example, Waxman Hatch ruling and European Community regulatory exclusivity) or if later, until the Market Exclusive Position of the Products ends through a generic entrant either into the US market or a major European market.",
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": "UNIVERSITY will promptly upon effectiveness of this agreement provide ACCESS with all the Know-How possessed by UNIVERSITY which is useful and necessary for ACCESS to perform the activities described in Article 5; UNIVERSITY shall disclose to and make available to ACCESS all Know-How possessed by UNIVERSITY and other information related to the Products which is requested by ACCESS to conduct formulation, preclinical and clinical studies; UNIVERSITY shall disclose to ACCESS all relevant Know-How relating to the Products which UNIVERSITY has developed or acquired or may hereafter develop or acquire during the term of this Agreement and which is necessary or helpful for ACCESS or its sublicensees",
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": "UNIVERSITY represents to ACCESS that to the best of its knowledge its Know-How or that the license and use by ACCESS of Know-How will not infringe any third-party ACCESS and UNIVERSITY patents.",
      "warranties_ip_sufficiency": "UNIVERSITY represents that it is the sole and exclusive owner of the Know-How and has not assigned, transferred or licensed or otherwise encumbered the Know-How or ACCESS and UNIVERSITY Patents; UNIVERSITY represents that it is not aware of any additional rights or licenses necessary for ACCESS to exercise the exclusive license granted hereunder.",
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [
        {
          "requirement_type": "Development Efforts",
          "description": "ACCESS shall use commercially reasonable efforts to conduct its designated development activities for the Products on a timely bases and will provide UNIVERSITY with a copy of its development guidelines and plan within 90 days of the Effective Date.",
          "timeline": null,
          "consequences": null
        },
        {
          "requirement_type": "Regulatory Approval",
          "description": "If ACCESS and/or a partner has been unable to enter into Phase 1 human trials and file for Regulatory Approval in the United States and two major European Countries for the Products by the milestone dates specified in Schedule C hereto, then, unless failure is due to UNIVERSITY not providing necessary data on a timely basis, UNIVERSITY shall have the unilateral right either (a) to extend the time for entry into Phase 1 human trials and/or filing for Regulatory Approval or (b), after consultation with ACCESS, the rights to the Products shall revert back to UNIVERSITY.",
          "timeline": null,
          "consequences": null
        },
        {
          "requirement_type": "NDA Approvals",
          "description": "ACCESS shall use commercially reasonable efforts to obtain NDA approvals and other government approvals in the major countries as listed in Schedule B in the Licensed Territory.",
          "timeline": null,
          "consequences": null
        }
      ],
      "confidential_agreement": true,
      "confidential_materials": "any data and information obtained from the other Party under this Agreement, including UNIVERSITY and ACCESS Patent information",
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "Schedule A",
          "type": null,
          "description": null,
          "reference_section": "1.01"
        },
        {
          "name": "Schedule B",
          "type": null,
          "description": null,
          "reference_section": "1.07"
        },
        {
          "name": "Schedule C",
          "type": null,
          "description": null,
          "reference_section": "5.01"
        }
      ],
      "governing_law": null,
      "jurisdiction": null,
      "termination_rights": "UNIVERSITY may as its sole remedy for such failure by ACCESS, terminate the Agreement with respect to such particular country of the Licensed Territory, provided that UNIVERSITY shall not exercise its right under this Section 8.05 in the event ACCESS or its sublicensees clearly demonstrates to UNIVERSITY that it is exercising due diligence in pursuing such NDA; If ACCESS fails to develop the Products in the Licensed Territory solely for scientific reasons, ACCESS shall promptly notify and explain to UNIVERSITY the situation. If UNIVERSITY regards such ACCESS failure as reasonable, each party may terminate this Agreement as its sole remedy.",
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/1997/10-K/0000318306-97-000003/EX-10.19.txt",
      "year": "1997",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:57:01.564252",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/1998/10-Q_A/0000318306-98-000012/EX-10.13.txt": {
    "contract": {
      "title": "AGREEMENT BETWEEN ACCESS PHARMACEUTICALS, INC. AND BLOCK DRUG COMPANY, INC. (Unknown)",
      "contract_type": "License Agreement",
      "summary": "This is a license agreement between Access Pharmaceuticals and Block Drug Company for a topical product containing amlexanox for treating aphthous ulcers. Access wishes to develop and seek partners to develop the product in various countries.",
      "execution_date": "1998-03-05",
      "effective_date": "1998-03-05",
      "expiration_date": null,
      "licensor": {
        "name": "Block Drug Company, Inc.",
        "address": "257 Cornelison Avenue, Jersey City, New Jersey 07302",
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "licensee": {
        "name": "Access Pharmaceuticals, Inc.",
        "address": "2600 Stemmons Freeway, Suite 176, Dallas, Texas 75207",
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "agreement_grants": "Block grants Access certain rights in and to a topical product for treating aphthous ulcers containing amlexanox. Access wishes to develop such product itself in various countries and to seek partners in various countries to develop such product.",
      "exclusivity_grant_type": null,
      "exclusivity_milestones": [],
      "right_to_sublicense": true,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": "Dermatological Use: all uses for the treatment of diseases and disorders of the integument including, but not limited to, therapeutic, prophylactic and immunological uses. For the purposes of this definition, integument is skin and its appendages, including hair, hair follicles, sebaceous glands, sweat glands, nails, and component and migratory cells of the skin.",
      "licensed_patents": [
        {
          "patent_number": "5",
          "patent_title": null,
          "filing_date": null,
          "issue_date": null
        }
      ],
      "licensed_products": [
        {
          "product_name": "Formulation",
          "description": "topical formulation containing Amlexanox",
          "category": "pharmaceutical"
        }
      ],
      "licensed_territory": [
        {
          "territory_name": "various countries",
          "territory_type": "unspecified",
          "restrictions": "unspecified"
        }
      ],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": "Block must allow Access to pay Takeda royalties to Block.",
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": "Improvements by Access",
      "licensee_right_to_improvements": true,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": false,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": false,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": "Audit Rights are mentioned in Paragraph 11.12",
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": true,
      "confidential_materials": "Access Know-How; Block Know-How",
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "Exhibit A",
          "type": null,
          "description": "the topical formulation containing Amlexanox",
          "reference_section": "1.13"
        },
        {
          "name": "Exhibit B",
          "type": null,
          "description": "all patents and applications",
          "reference_section": "1.16"
        }
      ],
      "governing_law": "New Jersey Law Applies",
      "jurisdiction": "New Jersey",
      "termination_rights": "Termination for Breach; Rights to Survive; Reversion and Termination for Failure to Pay Takeda License Fees; Termination by Takeda",
      "dispute_resolution": "Alternative Dispute Resolution",
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/1998/10-Q_A/0000318306-98-000012/EX-10.13.txt",
      "year": "1998",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:57:06.894660",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/1998/10-Q/0000318306-98-000007/EX-10.12.txt": {
    "contract": {
      "title": "LICENSE AGREEMENT BETWEEN STRAKAN LIMITED AND ACCESS PHARMACEUTICALS, INC. (Unknown)",
      "contract_type": "License Agreement",
      "summary": "This is a license agreement between Access Pharmaceuticals, Inc. and Strakan Ltd. for the development and commercial exploitation of a zinc compound patent for human use in dermatological and topical products. Strakan receives an exclusive global license.",
      "execution_date": "1998-02-26",
      "effective_date": "1998-02-26",
      "expiration_date": null,
      "licensor": {
        "name": "Access Pharmaceuticals, Inc.",
        "address": "2600 Stemmons Freeway, Suite 176, Dallas, TX 75207-2107",
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "Strakan Ltd.",
        "address": "22 Church Street, Hamilton HM11, Bermuda",
        "entity_type": "corporation",
        "jurisdiction": "Bermuda",
        "contact_info": null
      },
      "agreement_grants": "ACCESS grants to STRAKAN an exclusive license to use the KNOW-HOW and the TECHNOLOGY to make, have made, use, develop, modify, market, sell and have sold PRODUCT in the TERRITORY in the FIELD, and an exclusive license under the PATENTS to make, have made, use, develop, market, sell and have sold PRODUCT in the TERRITORY in the FIELD.",
      "exclusivity_grant_type": "Exclusive",
      "exclusivity_milestones": [],
      "right_to_sublicense": true,
      "sublicense_restrictions": [
        {
          "restriction_type": "Approval",
          "description": "Sublicensing to THIRD PARTIES is subject to ACCESS approval, not to be unreasonably withheld or delayed.",
          "conditions": "ACCESS will receive * percent of any sub-licensing milestone payments. If STRAKAN receives milestone payments other than in cash or an equity investment as part of a license agreement, the PARTIES agree to negotiate in good faith what portion should be received by ACCESS."
        }
      ],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": "dermatological and topical products for human use",
      "licensed_patents": [],
      "licensed_products": [
        {
          "product_name": "PRODUCT",
          "description": "any dermatological or topical products for human use developed pursuant to the terms of this LICENSE utilizing the PATENTS, TECHNOLOGY, KNOW-HOW or MANUFACTURE.",
          "category": "dermatological or topical products"
        }
      ],
      "licensed_territory": [
        {
          "territory_name": "the world",
          "territory_type": "global",
          "restrictions": null
        }
      ],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [
        {
          "requirement_type": "Development and Marketing Efforts",
          "description": "STRAKAN will undertake at its own cost, the timely performance of all formulation/clinical development work, regulatory actions and filings necessary to obtain APPROVAL for DEVELOPMENT PRODUCTS in markets listed in Appendix D.",
          "timeline": null,
          "consequences": null
        }
      ],
      "confidential_agreement": true,
      "confidential_materials": "TECHNOLOGY, PATENTS, any samples of PRODUCT, financial terms of this LICENSE, and business development plans for the PRODUCT",
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "Appendix A-Patents",
          "type": null,
          "description": null,
          "reference_section": null
        },
        {
          "name": "Appendix B-Major Markets",
          "type": null,
          "description": null,
          "reference_section": null
        },
        {
          "name": "Appendix C-Option Agreement",
          "type": null,
          "description": null,
          "reference_section": null
        },
        {
          "name": "Appendix D-Market Approval",
          "type": null,
          "description": null,
          "reference_section": null
        },
        {
          "name": "Appendix E-Clinical Trials Insurance",
          "type": null,
          "description": null,
          "reference_section": null
        }
      ],
      "governing_law": null,
      "jurisdiction": null,
      "termination_rights": "See Article 13",
      "dispute_resolution": "See Article 16",
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": "STRAKAN shall be responsible for any required governmental export license if any sublicensee participate or receive TECHNOLOGY."
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/1998/10-Q/0000318306-98-000007/EX-10.12.txt",
      "year": "1998",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:57:11.887606",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/1998/10-Q/0000318306-98-000008/EX-10.13.txt": {
    "contract": {
      "title": "AGREEMENT BETWEEN ACCESS PHARMACEUTICALS, INC. AND BLOCK DRUG COMPANY, INC. (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between Block Drug Company, Inc. (licensor) and Access Pharmaceuticals, Inc. (licensee). Grant type: Nonexclusive. Licenses 1 patent(s). Licenses 1 product(s). Territory: 1 region(s). Executed: 1998-03-05",
      "execution_date": "1998-03-05",
      "effective_date": null,
      "expiration_date": null,
      "licensor": {
        "name": "Block Drug Company, Inc.",
        "address": "257 Cornelison Avenue, Jersey City, New Jersey 07302",
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "licensee": {
        "name": "Access Pharmaceuticals, Inc.",
        "address": "2600 Stemmons Freeway, Suite 176, Dallas, Texas 75207",
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "agreement_grants": "Block grants Access rights to develop a topical product for treating aphthous ulcers containing amlexanox.",
      "exclusivity_grant_type": "Nonexclusive",
      "exclusivity_milestones": [],
      "right_to_sublicense": true,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": "Dermatological Use",
      "licensed_patents": [
        {
          "patent_number": "5",
          "patent_title": null,
          "filing_date": null,
          "issue_date": null
        }
      ],
      "licensed_products": [
        {
          "product_name": "Formulation",
          "description": "topical formulation containing Amlexanox",
          "category": "pharmaceutical"
        }
      ],
      "licensed_territory": [
        {
          "territory_name": "various countries",
          "territory_type": null,
          "restrictions": "Access wishes to develop such product itself in various countries and to seek partners in various countries to develop such product"
        }
      ],
      "contract_term": "variable end",
      "contract_term_details": "Term as defined in Article 9",
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": "Block must allow Access to pay Takeda Royalties to Block.",
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": true,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": false,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": false,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": "Power to Enter Into Agreement",
      "warranties_infringement": "Obligations Regarding Patent Infringement",
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": "non-transferable without agreement by licensor",
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": "Audit Rights",
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": true,
      "confidential_materials": "Access Know-How; Block Know-How",
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "Exhibit A",
          "type": null,
          "description": "topical formulation containing Amlexanox",
          "reference_section": "1.13"
        },
        {
          "name": "Exhibit B",
          "type": null,
          "description": "all patents and applications",
          "reference_section": "1.16"
        },
        {
          "name": "Exhibit C",
          "type": null,
          "description": "agreement between Chemex and Takeda dated 1987-11-12 regarding licensing of patent rights from Takeda to Chemex",
          "reference_section": "1.22"
        }
      ],
      "governing_law": "New Jersey Law Applies",
      "jurisdiction": "New Jersey",
      "termination_rights": "Termination for Breach; Rights to Survive; Reversion and Termination for Failure to Pay Takeda License Fees; Termination by Takeda",
      "dispute_resolution": "Alternative Dispute Resolution",
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/1998/10-Q/0000318306-98-000008/EX-10.13.txt",
      "year": "1998",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:57:17.171665",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/1998/10-Q/0000318306-98-000008/EX-10.15.txt": {
    "contract": {
      "title": "REGISTRATION RIGHTS AGREEMENT (Unknown)",
      "contract_type": "Registration Rights Agreement",
      "summary": "This is a registration rights agreement between Access Pharmaceuticals, Inc. and the investors listed on Schedule I, regarding the registration of resale of shares under the Securities Act of 1933.",
      "execution_date": null,
      "effective_date": null,
      "expiration_date": null,
      "licensor": {
        "name": "Access Pharmaceuticals, Inc.",
        "address": null,
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "Investors listed on Schedule I",
        "address": null,
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "agreement_grants": "The Company desires to undertake to register under the Securities Act, the resale of the Shares, in accordance with the terms hereof.",
      "exclusivity_grant_type": null,
      "exclusivity_milestones": [],
      "right_to_sublicense": false,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [
        {
          "product_name": "Bridge Offering Shares",
          "description": "166,667 shares of Common Stock, par value $.04 per share",
          "category": "Common Stock"
        },
        {
          "product_name": "Warrants",
          "description": "to purchase 166,667 shares",
          "category": "Warrants"
        },
        {
          "product_name": "Warrant Shares",
          "description": null,
          "category": null
        },
        {
          "product_name": "Primary Offering Shares",
          "description": null,
          "category": "Common Stock"
        }
      ],
      "licensed_territory": [],
      "contract_term": "variable end",
      "contract_term_details": "at least seven years after the close of the Company's Private Placement, or such shorter period as prescribed by Rule 144, or until there are no more Registrable Securities",
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": "Prepare and file registration statements with the SEC; furnish copies of prospectuses; register and qualify Registrable Securities under Blue Sky laws; enter into underwriting agreements; notify investors of events affecting the prospectus; prevent the issuance of stop orders; permit counsel to review registration statements; make earnings statements available; furnish opinions and letters to underwriters; make records available for inspection; use best efforts to list Registrable Securities; provide a transfer agent and registrar; facilitate the delivery of certificates; expedite disposition of Registrable Securities.",
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": "Each Investor agrees that, upon receipt of any notice from the Company of the happening of any event of the kind described in Section 2(f), such Investor will immediately discontinue disposition of Registrable Securities pursuant to the Registration Statement covering such Registrable Securities until such Investor's receipt of the copies of the supplemented or amended prospectus contemplated by Section 2(f)",
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": "non-transferable without agreement by licensor",
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "Schedule I",
          "type": null,
          "description": "List of Investors",
          "reference_section": null
        }
      ],
      "governing_law": null,
      "jurisdiction": null,
      "termination_rights": null,
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/1998/10-Q/0000318306-98-000008/EX-10.15.txt",
      "year": "1998",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:57:22.957051",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/1998/10-Q/0000318306-98-000008/EX-10.14.txt": {
    "contract": {
      "title": "SALES AGENCY AGREEMENT (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between Access Pharmaceuticals, Inc. (licensor) and Sunrise Securities Corp. (licensee). Grant type: Exclusive. Licenses 1 product(s). Territory: 1 region(s). Executed: 1998-06-18",
      "execution_date": "1998-06-18",
      "effective_date": null,
      "expiration_date": null,
      "licensor": {
        "name": "Access Pharmaceuticals, Inc.",
        "address": "Delaware corporation",
        "entity_type": null,
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "Sunrise Securities Corp.",
        "address": "135 E. 57th Street New York, New York 10022",
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "agreement_grants": "The Company hereby appoints you as its Placement Agent and grants to you the exclusive right to offer, as its agent, the Shares pursuant to the terms of this Agreement.",
      "exclusivity_grant_type": "Exclusive",
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [
        {
          "product_name": "Shares of Common Stock",
          "description": "minimum of 18666667 and a maximum of 52000000 shares of common stock, par value $.04 per share",
          "category": null
        }
      ],
      "licensed_territory": [
        {
          "territory_name": "United States",
          "territory_type": "Country",
          "restrictions": null
        }
      ],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "Exhibit I",
          "type": null,
          "description": "form of Selected Dealer Agreement",
          "reference_section": "2(f)"
        },
        {
          "name": "Exhibit II",
          "type": null,
          "description": "Placement Agent Warrants",
          "reference_section": "4(b)"
        }
      ],
      "governing_law": null,
      "jurisdiction": "New York",
      "termination_rights": "The agency created hereby is not terminable by the Company except upon termination of the Offering pursuant to the terms of this Agreement or upon expiration of the Offering Period (as hereinafter defined) in accordance with the terms of this Agreement.",
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/1998/10-Q/0000318306-98-000008/EX-10.14.txt",
      "year": "1998",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:57:26.435379",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/1998/10-K/0000318306-98-000004/EX-10.11.txt": {
    "contract": {
      "title": "Agreement of Merger and Plan of Reorganization (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between Access Pharmaceuticals, Inc. (licensor) and Tacora Corporation (licensee). Grant type: Nonexclusive. Licenses 5 product(s). Upfront payment: $600,000.00. Territory: 2 region(s). Executed: 1997-05-23",
      "execution_date": "1997-05-23",
      "effective_date": "1997-05-23",
      "expiration_date": null,
      "licensor": {
        "name": "Access Pharmaceuticals, Inc.",
        "address": "Dallas, Texas",
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "Tacora Corporation",
        "address": null,
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "agreement_grants": "Acquirer shall be merged into Target upon the terms and subject to the conditions set forth in this Agreement.",
      "exclusivity_grant_type": "Nonexclusive",
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": "oncology; antigen/adjuvant; ultrasound triggered release condensed particle therapeutic system; additional field of use",
      "licensed_patents": [],
      "licensed_products": [
        {
          "product_name": "Cisplatin",
          "description": "polymer platinates based on animal efficacy and toxicity achieving the EORTC's predetermined parameters",
          "category": "oncology compound"
        },
        {
          "product_name": "Tacora oncology compound",
          "description": null,
          "category": "oncology compound"
        },
        {
          "product_name": "pore-forming protein",
          "description": null,
          "category": null
        },
        {
          "product_name": "antigen/adjuvant",
          "description": null,
          "category": null
        },
        {
          "product_name": "ultrasound triggered release condensed particle therapeutic system",
          "description": null,
          "category": null
        }
      ],
      "licensed_territory": [
        {
          "territory_name": "United States",
          "territory_type": "Country",
          "restrictions": null
        },
        {
          "territory_name": "Europe",
          "territory_type": "Region",
          "restrictions": null
        }
      ],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": 600000.0,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": "non-transferable without agreement by licensor",
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [
        {
          "requirement_type": "Milestone",
          "description": "EORTC approval to initiate human studies with Cisplatin or other polymer platinates based on animal efficacy and toxicity achieving the EORTC's predetermined parameters.",
          "timeline": "45 days after the Milestone Closing Date",
          "consequences": null
        },
        {
          "requirement_type": "Milestone",
          "description": "Completion of Phase I/II study with Cisplatin and agreement by the technology development committee to proceed to Phase III or Phase II B Studies.",
          "timeline": "45 days after the Milestone Closing Date",
          "consequences": null
        },
        {
          "requirement_type": "Milestone",
          "description": "Commercial alliance for Cisplatin development.",
          "timeline": "45 days after the Milestone Closing Date",
          "consequences": null
        },
        {
          "requirement_type": "Milestone",
          "description": "Commencing process of commercialization of one additional Tacora oncology compound and EORTC or IND approval of Phase I studies.",
          "timeline": "90 days after the Milestone Closing Date",
          "consequences": null
        },
        {
          "requirement_type": "Milestone",
          "description": "Loaded particle with triggered pore stable in plasma with positive efficacy in an animal model with agreement to proceed to development.",
          "timeline": "90 days after the Milestone Closing Date",
          "consequences": null
        },
        {
          "requirement_type": "Milestone",
          "description": "Filing of an IND for a product being developed under the Mayo/Fernandez technology license.",
          "timeline": "90 days after the Milestone Closing Date",
          "consequences": null
        },
        {
          "requirement_type": "Milestone",
          "description": "Acceptance for publication of \"Landmark\" manuscript in Nature, Science or a journal of similar stature including the Journal of Controlled Release.",
          "timeline": "0 days after the Milestone Closing Date",
          "consequences": null
        },
        {
          "requirement_type": "Milestone",
          "description": "Successful formulation of antigen/adjuvant with in vivo proof of principal of incremental efficacy.",
          "timeline": "90 days after the Milestone Closing Date",
          "consequences": null
        },
        {
          "requirement_type": "Milestone",
          "description": "Completion of commercial alliance with an antigen/adjuvant to commence development.",
          "timeline": "45 days after the Milestone Closing Date",
          "consequences": null
        },
        {
          "requirement_type": "Milestone",
          "description": "U.S. notice of allowance of Cisplatin patent covering product development.",
          "timeline": "0 days after the Milestone Closing Date",
          "consequences": null
        },
        {
          "requirement_type": "Milestone",
          "description": "European Patent Office Notice of Allowance of Cisplatin patent covering product development.",
          "timeline": "0 days after the Milestone Closing Date",
          "consequences": null
        },
        {
          "requirement_type": "Milestone",
          "description": "U.S. notice of allowance of pore-forming protein patent or new Tacora core patent.",
          "timeline": "0 days after the Milestone Closing Date",
          "consequences": null
        },
        {
          "requirement_type": "Milestone",
          "description": "European Patent Office Notice of Allowance of pore-forming protein patent or new Tacora patent.",
          "timeline": "0 days after the Milestone Closing Date",
          "consequences": null
        },
        {
          "requirement_type": "Milestone",
          "description": "Commercial agreement to develop an ultrasound triggered release condensed particle therapeutic system.",
          "timeline": "90 days after the Milestone Closing Date",
          "consequences": null
        },
        {
          "requirement_type": "Milestone",
          "description": "Commercial agreement to develop a product in an additional field of use.",
          "timeline": "0 days after the Milestone Closing Date",
          "consequences": null
        }
      ],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "Exhibit A",
          "type": "Certificate",
          "description": "Form of Certificate of Merger",
          "reference_section": "1.1"
        }
      ],
      "governing_law": "laws of the State of Delaware",
      "jurisdiction": null,
      "termination_rights": "paragraph 13",
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/1998/10-K/0000318306-98-000004/EX-10.11.txt",
      "year": "1998",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:57:34.138170",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/1999/10-Q/0000318306-99-000014/EX-10.19.txt": {
    "contract": {
      "title": "REGISTRATION RIGHTS AGREEMENT (Unknown)",
      "contract_type": "License Agreement",
      "summary": "This is a Registration Rights Agreement between Access Pharmaceuticals, Inc. and the investors listed on Schedule I, regarding the registration of the resale of shares of common stock purchased in a private placement.",
      "execution_date": null,
      "effective_date": null,
      "expiration_date": null,
      "licensor": {
        "name": "Access Pharmaceuticals, Inc.",
        "address": "State of Delaware",
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "Investors",
        "address": "Schedule I",
        "entity_type": "investors",
        "jurisdiction": null,
        "contact_info": null
      },
      "agreement_grants": "The Company undertakes to register under the Securities Act, the resale of the Shares, in accordance with the terms hereof.",
      "exclusivity_grant_type": null,
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [
        {
          "product_name": "Shares",
          "description": "shares of common stock, $.01 par value per share",
          "category": "Common Stock"
        }
      ],
      "licensed_territory": [],
      "contract_term": "fixed end date",
      "contract_term_details": "at least two years after the final closing of the Company's Private Placement, or such shorter period as prescribed by Rule 144, or until there are no more Registrable Securities",
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": "Prepare and file registration statements with the SEC; keep registration statements effective; furnish copies of prospectuses; register and qualify Registrable Securities under Blue Sky laws; enter into underwriting agreements; notify investors of material events; prevent stop orders; permit counsel review; make earnings statements available; furnish opinions and letters to underwriters; make records available for inspection; list Registrable Securities on exchanges; provide a transfer agent and registrar; facilitate delivery of certificates.",
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [],
      "governing_law": null,
      "jurisdiction": null,
      "termination_rights": null,
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/1999/10-Q/0000318306-99-000014/EX-10.19.txt",
      "year": "1999",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:57:37.583195",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/1999/10-Q/0000318306-99-000014/EX-10.18.txt": {
    "contract": {
      "title": "SALES AGENCY AGREEMENT (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between Access Pharmaceuticals, Inc. (licensor) and Sunrise Securities Corp. (licensee). Grant type: Exclusive. Licenses 1 product(s). Territory: 1 region(s). Executed: 1999-07-20",
      "execution_date": "1999-07-20",
      "effective_date": null,
      "expiration_date": null,
      "licensor": {
        "name": "Access Pharmaceuticals, Inc.",
        "address": "Delaware corporation",
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "licensee": {
        "name": "Sunrise Securities Corp.",
        "address": "135 E. 57th Street New York, New York 10022",
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "agreement_grants": "The Company hereby appoints you as its Placement Agent and grants to you the exclusive right to offer, as its agent, the Shares pursuant to the terms of this Agreement.",
      "exclusivity_grant_type": "Exclusive",
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [
        {
          "product_name": "Shares of Common Stock",
          "description": "par value $.01 per share",
          "category": null
        }
      ],
      "licensed_territory": [
        {
          "territory_name": "New York",
          "territory_type": "State",
          "restrictions": null
        }
      ],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": false,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": false,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": "Squadron, Ellenoff, Plesent & Sheinfeld, LLP (\"SEP&S\")",
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "Exhibit I",
          "type": null,
          "description": "form of Selected Dealer Agreement",
          "reference_section": "2(f)"
        },
        {
          "name": "Exhibit II",
          "type": null,
          "description": "Placement Agent Warrants",
          "reference_section": "4(b)"
        }
      ],
      "governing_law": null,
      "jurisdiction": "New York",
      "termination_rights": "The agency created hereby is not terminable by the Company except upon termination of the Offering pursuant to the terms of this Agreement or upon expiration of the Offering Period (as hereinafter defined) in accordance with the terms of this Agreement.",
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/1999/10-Q/0000318306-99-000014/EX-10.18.txt",
      "year": "1999",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:57:41.266000",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/1999/10-K/0000318306-99-000004/EX-10.17.txt": {
    "contract": {
      "title": "LICENSE AGREEMENT BETWEEN BLOCK DRUG COMPANY AND ACCESS PHARMACEUTICALS, INC. (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between Block Drug Company, Inc. (licensor) and Access Pharmaceuticals, Inc. (licensee). Grant type: Exclusive. Licenses 1 patent(s). Licenses 1 product(s). Territory: 1 region(s). Executed: 1998-12-21",
      "execution_date": "1998-12-21",
      "effective_date": "1998-12-21",
      "expiration_date": null,
      "licensor": {
        "name": "Block Drug Company, Inc.",
        "address": "257 Cornelison Avenue, Jersey City, New Jersey 07302",
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "licensee": {
        "name": "Access Pharmaceuticals, Inc.",
        "address": "2600 Stemmons Freeway, Suite 176, Dallas, Texas 75207",
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "agreement_grants": "Block grants Access the exclusive right under the Licensed Patents and the Block Know-How to make, use, have made and sell or have sold any Product within the Territory during the Term, including the right to make or have made outside the Territory for sale in Territory. The rights granted hereunder, however, are subject to the rights granted to Block Takeda as set forth in the Takeda License Agreement and the Takeda Supply Agreement.",
      "exclusivity_grant_type": "Exclusive",
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": "treatment of chemotherapy or radiation-induced inflammation of the oral mucous membrane and inflammation of the oral mucous membrane in immuno compromised patients",
      "licensed_patents": [
        {
          "patent_number": "5,362,737",
          "patent_title": "Methods of Treating Aphthous Ulcers and Other Mucocutaneous Disorders with Amlexanox",
          "filing_date": null,
          "issue_date": null
        }
      ],
      "licensed_products": [
        {
          "product_name": "topical formulation containing Amlexanox for Oral Mucositis Use/Mucositis Indication",
          "description": "excluding any formulation as described in the Block Access Agreement or the Block Chemex Agreement",
          "category": null
        }
      ],
      "licensed_territory": [
        {
          "territory_name": "all countries in the world except Japan",
          "territory_type": null,
          "restrictions": "where Block has granted rights under the Takeda License Agreement and the Takeda Supply Agreement to Takeda which includes Japan"
        }
      ],
      "contract_term": "variable end",
      "contract_term_details": "Term of this Agreement, as set forth in Article 6",
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": "non-transferable without agreement by licensor",
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": "8.12 Audit Rights",
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": true,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "EX-10.17",
          "type": null,
          "description": "LICENSE AGREEMENT BETWEEN BLOCK DRUG COMPANY AND ACCESS PHARMACEUTICALS, INC. DATED DECEMBER 21, 1998",
          "reference_section": null
        },
        {
          "name": "EXHIBIT 10.17",
          "type": null,
          "description": "Agreement Between Access Pharmaceuticals, Inc. And Block Drug Company, Inc. 12/17/98",
          "reference_section": null
        }
      ],
      "governing_law": "New Jersey Law Applies",
      "jurisdiction": null,
      "termination_rights": "Article 6",
      "dispute_resolution": "Alternative Dispute Resolution",
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/1999/10-K/0000318306-99-000004/EX-10.17.txt",
      "year": "1999",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:57:46.208847",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2000/10-Q/0000318306-00-000009/EX-10.23.txt": {
    "contract": {
      "title": "REGISTRATION RIGHTS AGREEMENT (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between Access Pharmaceuticals, Inc. (licensor) and Investors (licensee). Grant type: Nonexclusive. Licenses 1 product(s). Territory: 1 region(s)",
      "execution_date": null,
      "effective_date": null,
      "expiration_date": null,
      "licensor": {
        "name": "Access Pharmaceuticals, Inc.",
        "address": "State of Delaware",
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "Investors",
        "address": null,
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "agreement_grants": "The Company desires to undertake to register under the Securities Act, the resale of the Shares, in accordance with the terms hereof.",
      "exclusivity_grant_type": "Nonexclusive",
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [
        {
          "product_name": "Shares",
          "description": "shares of common stock, $.01 par value per share",
          "category": "Common Stock"
        }
      ],
      "licensed_territory": [
        {
          "territory_name": "United States",
          "territory_type": "Country",
          "restrictions": "Governed by the Securities Act of 1933"
        }
      ],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": "Prepare and file registration statements with the SEC; keep registration statements effective; furnish prospectuses to investors; register and qualify securities under Blue Sky laws; enter into underwriting agreements; notify investors of material events; prevent stop orders; permit counsel review; make earnings statements available; furnish opinions and letters to underwriters; make records available for inspection; list securities on exchanges; provide transfer agent and registrar; facilitate delivery of certificates.",
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [],
      "governing_law": "the Securities Act of 1933",
      "jurisdiction": null,
      "termination_rights": null,
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2000/10-Q/0000318306-00-000009/EX-10.23.txt",
      "year": "2000",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:57:49.483739",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2000/10-Q/0000318306-00-000009/EX-10.22.txt": {
    "contract": {
      "title": "SALES AGENCY AGREEMENT (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between Access Pharmaceuticals, Inc. (licensor) and Sunrise Securities Corp. (licensee). Grant type: Exclusive. Licenses 1 product(s). Executed: 2000-02-29",
      "execution_date": "2000-02-29",
      "effective_date": null,
      "expiration_date": null,
      "licensor": {
        "name": "Access Pharmaceuticals, Inc.",
        "address": "Delaware corporation",
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "Sunrise Securities Corp.",
        "address": "135 E. 57th Street New York, New York 10022",
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": "Dear Sirs:"
      },
      "agreement_grants": "The Company hereby appoints you as its Placement Agent and grants to you the exclusive right to offer, as its agent, the Shares pursuant to the terms of this Agreement.",
      "exclusivity_grant_type": "Exclusive",
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [
        {
          "product_name": "Shares of Common Stock",
          "description": "par value $.01 per share",
          "category": "Common Stock"
        }
      ],
      "licensed_territory": [],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "Exhibit I",
          "type": "form",
          "description": "form of Selected Dealer Agreement",
          "reference_section": "2(f)"
        },
        {
          "name": "Exhibit II",
          "type": "form",
          "description": "Placement Agent Warrants",
          "reference_section": "4(b)"
        }
      ],
      "governing_law": null,
      "jurisdiction": "New York",
      "termination_rights": "The agency created hereby is not terminable by the Company except upon termination of the Offering pursuant to the terms of this Agreement or upon expiration of the Offering Period (as hereinafter defined) in accordance with the terms of this Agreement.",
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2000/10-Q/0000318306-00-000009/EX-10.22.txt",
      "year": "2000",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:57:52.619870",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2000/10-K/0000318306-00-000003/EX-10.19.txt": {
    "contract": {
      "title": "EMPLOYMENT AGREEMENT OF DAVID P. NOWOTNIK, PH.D. (Unknown)",
      "contract_type": "Employment Agreement",
      "summary": "License agreement between ACCESS Pharmaceuticals, Inc. (licensor) and David P. Nowotnik, Ph.D. (licensee). Executed: 1998-11-16",
      "execution_date": "1998-11-16",
      "effective_date": null,
      "expiration_date": null,
      "licensor": {
        "name": "ACCESS Pharmaceuticals, Inc.",
        "address": "2600 Stemmons Freeway, Suite 176, Dallas, Texas 75207-2107",
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "David P. Nowotnik, Ph.D.",
        "address": "1018 San Jacinto Drive, #1516, Irving, TX 75063",
        "entity_type": "individual",
        "jurisdiction": null,
        "contact_info": null
      },
      "agreement_grants": "The Company agrees to employ Executive and Executive agrees to be employed upon the terms and conditions hereinafter set forth. During the term of this Agreement, Executive shall serve as the Vice President of Research and Development of the Company.",
      "exclusivity_grant_type": null,
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": "Research and Development",
      "licensed_patents": [],
      "licensed_products": [],
      "licensed_territory": [],
      "contract_term": "variable end",
      "contract_term_details": "The employment of the Executive hereunder shall begin on the date hereof and shall continue in full force and effect for a period of one (1) year, and thereafter shall be automatically renewed for successive one-year periods unless the Company gives the Executive written notice of termination within six (6) months prior to the end of any such period or until the occurrence of a Termination Date, as defined in Section 5 (the \"Term\").",
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [],
      "governing_law": null,
      "jurisdiction": null,
      "termination_rights": "5.  Termination Date; Consequences for Compensation and Benefits\n5.1. Definition of Termination Date. The first to occur of the following events shall be the Termination Date:\n5.1.1 The date on which the Executive becomes entitled to receive long- term disability payments by reason of total and permanent disability;\n5.1.2. The Executive's death;\n5.1.3. Voluntary resignation after one of the following events shall have occurred, which event shall be specified to the Company by the Executive at the time of resignation: material reduction in the responsibility, authority, power or duty of the Executive or a material breach by the Company of any provision of this Agreement, which breach continues for 30 days following notice by the  Executive to the Company setting forth the nature of the breach (\"Resignation with Reason\");\n5.1.4. Voluntary resignation not accompanied by a notice of reason described in Section 5.1.3 (\"General Resignation\");\n5.1.5 Discharge of the Executive by the Company after one of the following events shall have occurred, which event shall be specified in writing to the Executive by the Company at the time of discharge: (i) a felonious act committed by Executive during his employment hereunder, (ii) any act or omission on the part of Executive not requested or approved by the Company constituting willful malfeasance or gross negligence in the performance of his duties hereunder, (iii) conviction of the Executive or the entry of a plea of guilty or nolo contendere by the Executive to any crime involving moral turpitude, (iv) any material breach of any term of this Agreement by the Executive which is not cured within 30 days after written notice from the President of the Company to the Employee setting forth the nature of the breach (\"Discharge for Cause\"); For purposes of this subparagraph (5.1.5), no act or failure to act on the Executive's part shall be considered \"willful\" unless done or omitted to be done by Executive not in good faith and without reasonable belief that Executive's action or omission was in the best interest of the  Company. Notwithstanding the foregoing, Executive shall not be deemed to have been discharged for Cause unless and until there shall have been delivered to Executive a copy of a Notice of Termination (as defined below) from the President of the Company stating that in his good faith opinion Executive was guilty of conduct set forth in clauses (i), (ii), (iii) or (iv) above of this subparagraph (5.1.5) and specifying the particulars thereof in detail.\n5.1.6 Discharge of the Executive by the Company not accompanied by a notice of cause described in Section 5.1.5 (\"General Discharge\"). For purposes of this Agreement \"Notice of Termination\" shall mean a notice which indicates the specific termination provision in this Agreement relied upon and sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of Executive's employment under the provision so indicated. Each Notice of Termination shall be delivered at least sixty (60) days prior to the effective date of termination.",
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2000/10-K/0000318306-00-000003/EX-10.19.txt",
      "year": "2000",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:57:59.507742",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2000/10-K/0000318306-00-000003/EX-10.20.txt": {
    "contract": {
      "title": "401(K) PLAN (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between The Guardian Insurance & Annuity Company, Inc. (licensor) and Access Pharmaceuticals, Inc. 401(K) Savings Plan (licensee)",
      "execution_date": null,
      "effective_date": "1998-12-01",
      "expiration_date": null,
      "licensor": {
        "name": "The Guardian Insurance & Annuity Company, Inc.",
        "address": "Customer Service Office: PO Box 26280 Lehigh VAlley, PA 18002-6280; Executive Office: 201 Park Avenue South New York, NY 10003",
        "entity_type": "Stock Company",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "Access Pharmaceuticals, Inc. 401(K) Savings Plan",
        "address": null,
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "agreement_grants": "The Guardian Insurance & Annuity Company, Inc. will pay the benefits provided by this Contract in accordance with its provisions.",
      "exclusivity_grant_type": null,
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [],
      "licensed_territory": [],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [],
      "governing_law": null,
      "jurisdiction": null,
      "termination_rights": "Termination of the Contract described in Section 11.2",
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2000/10-K/0000318306-00-000003/EX-10.20.txt",
      "year": "2000",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:58:02.761970",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2001/10-Q/0000318306-01-500012/EX-10.19.txt": {
    "contract": {
      "title": "SUPPLEMENTAL LEASE AGREEMENT (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between POLLOCK REALTY CORPORATION (licensor) and Access Pharmaceuticals, Inc. (licensee). Grant type: Nonexclusive. Territory: 1 region(s). Executed: 2001-02-09",
      "execution_date": "2001-02-09",
      "effective_date": null,
      "expiration_date": null,
      "licensor": {
        "name": "POLLOCK REALTY CORPORATION",
        "address": "c/o TIG Real Estate Services, Inc. P. O. Box 802047 Dallas, Texas 75380-2047",
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": "PHONE: 972-661-0232; FAX: 972-661-0235"
      },
      "licensee": {
        "name": "Access Pharmaceuticals, Inc.",
        "address": "2600 Stemmons Freeway, Suite 164-176 Dallas, Texas 75207-2107",
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": "PHONE: 214-905-5100; FAX: 214-905-5101"
      },
      "agreement_grants": "Modifies the original Lease Agreement between Pollock Realty Corporation and Access Pharmaceuticals, Inc. dated 1996-07-25. Effective 2001-03-15, the Premises shall include Suites 164-176 and the rentable square footage contained in the Premises is deemed to be 11684 net rentable square feet and the rentable square footage of the Building is deemed to be 39733 net rentable square feet and Tenant's proportionate share of the Building is 29.41%",
      "exclusivity_grant_type": "Nonexclusive",
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [],
      "licensed_territory": [
        {
          "territory_name": "County of Dallas, City of Dallas and the State of Texas",
          "territory_type": null,
          "restrictions": null
        }
      ],
      "contract_term": "fixed end date",
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "EXHIBIT A",
          "type": null,
          "description": "ADJACENT PREMISES 2600 Stemmons Freeway Site Plan",
          "reference_section": null
        }
      ],
      "governing_law": null,
      "jurisdiction": null,
      "termination_rights": "Tenant has the option to terminate this Supplemental Lease Agreement according to the dates and terms set forth in section 5, conditioned upon Tenant's providing prior notice to Landlord through registered or certified mail and upon the payment schedule as follows to Landlord:\n* Effective 2003-04-01= 60000.00 plus all unamortized tenant improvements and all unamortized commissions (44772.00)\n* Effective 2004-04-01= 50000.00 plus all unamortized tenant improvements and all unamortized commissions (29850.00)\n* Effective 2005-04-01= 40000.00 plus all unamortized tenant improvements and all unamortized commissions (14925.00)\nNotice of Tenant's intention to terminate this Lease Agreement and payment of termination fee must be received by Landlord in writing not less than one hundred eighty (180) days prior to the to the effective date of termination.",
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2001/10-Q/0000318306-01-500012/EX-10.19.txt",
      "year": "2001",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:58:07.188000",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2002/10-Q/0000318306-02-000010/EX-10.27.txt": {
    "contract": {
      "title": "ASSET SALE AGREEMENT (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between Block Drug Company, Inc. (licensor) and Access Pharmaceuticals, Inc. (licensee). Licenses 2 product(s). Territory: 1 region(s). Executed: 2002-07-22",
      "execution_date": "2002-07-22",
      "effective_date": null,
      "expiration_date": null,
      "licensor": {
        "name": "Block Drug Company, Inc.",
        "address": "New Jersey",
        "entity_type": "corporation",
        "jurisdiction": "New Jersey",
        "contact_info": null
      },
      "licensee": {
        "name": "Access Pharmaceuticals, Inc.",
        "address": "Delaware",
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "agreement_grants": "Block sells and assigns the Purchased Assets and Inventory, and the Takeda License Agreement to Access.",
      "exclusivity_grant_type": null,
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": "manufacture, use, sale and distribution of the Products",
      "licensed_patents": [],
      "licensed_products": [
        {
          "product_name": "Aphthasol Product",
          "description": "a topical oral paste formulation containing Amlexanox currently approved by the FDA for use in the treatment of aphthous ulcers",
          "category": null
        },
        {
          "product_name": "Dermatological Product(s)",
          "description": "a topical preparation containing Amlexanox for use in the treatment of diseases and disorders of the mucocutaneous membrane and/or integument including, but not limited to, therapeutic, prophylactic and immunological uses. For the purposes of this definition, \"mucocutaneous membrane\" is skin and mucous membrane, and \"integument\" is skin and its appendages, including hair, hair follicles, sebaceous glands, sweat glands, nails and component and migratory cells of the skin. Dermatological Products shall include, without limitation, the Aphthasol Product and Mucositis Product;",
          "category": null
        }
      ],
      "licensed_territory": [
        {
          "territory_name": "U.S.",
          "territory_type": null,
          "restrictions": null
        }
      ],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "Exhibit A",
          "type": null,
          "description": "Aphthasol Agreement",
          "reference_section": "Aphthasol Agreement"
        },
        {
          "name": "Exhibit B",
          "type": null,
          "description": "Aphthasol Supply Agreement",
          "reference_section": "Aphthasol Supply Agreement"
        },
        {
          "name": "Exhibit C",
          "type": null,
          "description": "Aphthasol Trademarks Assignment",
          "reference_section": "Aphthasol Trademarks Assignment"
        },
        {
          "name": "Exhibit D",
          "type": null,
          "description": "Assignment and Assumption Agreement",
          "reference_section": "Assignment and Assumption Agreement"
        },
        {
          "name": "Exhibit E",
          "type": null,
          "description": "Bill of Sale and Assignment Agreement",
          "reference_section": "Bill of Sale and Assignment Agreement"
        },
        {
          "name": "Exhibit F",
          "type": null,
          "description": "Block/Chemex Agreement",
          "reference_section": "Block/Chemex Agreement"
        },
        {
          "name": "Exhibit G",
          "type": null,
          "description": "Inventory Bill of Sale and Assignment Agreement",
          "reference_section": "Inventory Bill of Sale and Assignment Agreement"
        }
      ],
      "governing_law": "Not specified in the provided text.",
      "jurisdiction": "Not specified in the provided text.",
      "termination_rights": "Not specified in the provided text.",
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2002/10-Q/0000318306-02-000010/EX-10.27.txt",
      "year": "2002",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:58:12.412133",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2002/10-Q/0000318306-02-000005/EX-10.26.txt": {
    "contract": {
      "title": "ASSET SALE AGREEMENT (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between BIOA PTY LIMITED (licensor) and ACCESS PHARMACEUTICALS AUSTRALIA PTY LIMITED (licensee). Upfront payment: $500,000.00. Executed: 2002-02-26",
      "execution_date": "2002-02-26",
      "effective_date": null,
      "expiration_date": null,
      "licensor": {
        "name": "BIOA PTY LIMITED",
        "address": "28 Barcoo Street, Roseville, NSW 2069",
        "entity_type": "PTY LIMITED",
        "jurisdiction": "Australia",
        "contact_info": null
      },
      "licensee": {
        "name": "ACCESS PHARMACEUTICALS AUSTRALIA PTY LIMITED",
        "address": "23 Greenfield Avenue, Middle Cove, NSW 2068",
        "entity_type": "PTY LIMITED",
        "jurisdiction": "Australia",
        "contact_info": null
      },
      "agreement_grants": "The Vendors as beneficial owners agree to sell and assign the Assets to the Purchaser free from any Encumbrance and the Purchaser agrees to purchase and acquire the Assets free from any Encumbrance, as at and with effect from Completion for the Purchase Consideration.",
      "exclusivity_grant_type": null,
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": "research and development of drug delivery technology including the VB12 Platform Technology, folate targeting technology and nano- particle networks with a view to commercialisation",
      "licensed_patents": [],
      "licensed_products": [],
      "licensed_territory": [],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": 500000.0,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "PLANT AND EQUIPMENT",
          "type": null,
          "description": null,
          "reference_section": "SCHEDULE 1"
        },
        {
          "name": "INTELLECTUAL PROPERTY",
          "type": null,
          "description": null,
          "reference_section": "SCHEDULE 2"
        },
        {
          "name": "EMPLOYEES",
          "type": null,
          "description": null,
          "reference_section": "SCHEDULE 3"
        },
        {
          "name": "WARRANTIES",
          "type": null,
          "description": null,
          "reference_section": "SCHEDULE 4"
        },
        {
          "name": "SCHEDULE OF EXCEPTIONS",
          "type": null,
          "description": null,
          "reference_section": "SCHEDULE 5"
        },
        {
          "name": "ASSIGNMENT DEED",
          "type": null,
          "description": null,
          "reference_section": "SCHEDULE 6"
        },
        {
          "name": "FORM OF WARRANT",
          "type": null,
          "description": null,
          "reference_section": "SCHEDULE 7"
        }
      ],
      "governing_law": "Governing Law and Jurisdiction",
      "jurisdiction": "Governing Law and Jurisdiction",
      "termination_rights": "Not applicable",
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2002/10-Q/0000318306-02-000005/EX-10.26.txt",
      "year": "2002",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:58:16.639517",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2002/10-K/0000318306-02-000003/EX-10.25.txt": {
    "contract": {
      "title": "1995 Stock Option Plan Amendment (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement with basic terms extracted",
      "execution_date": null,
      "effective_date": "2001-05-21",
      "expiration_date": null,
      "licensor": {
        "name": "Access Pharmaceuticals, Inc.",
        "address": null,
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "licensee": null,
      "agreement_grants": "Grants Nonstatutory Option for the purchase of 10,000 shares of Stock to each Non-Employee Director on the date of each Annual Meeting of the Stockholders of Company. Grants Nonstatutory Option to purchase 20,000 shares of Stock to a Non-Employee Director initially elected or appointed by the Board of Directors.",
      "exclusivity_grant_type": null,
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [],
      "licensed_territory": [],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "EX-10.25 3 r10k-003.txt",
          "type": "Amendment",
          "description": "STOCK PLAN AMENDMENT EXHIBIT 10.25",
          "reference_section": null
        }
      ],
      "governing_law": null,
      "jurisdiction": null,
      "termination_rights": null,
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2002/10-K/0000318306-02-000003/EX-10.25.txt",
      "year": "2002",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:58:22.637080",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2002/10-K/0000318306-02-000003/EX-10.24.txt": {
    "contract": {
      "title": "Supplemental Lease Agreement (Unknown)",
      "contract_type": "Lease Agreement",
      "summary": "License agreement between POLLOCK REALTY CORPORATION (licensor) and Access Pharmaceuticals, Inc. (licensee). Upfront payment: $42,000.00. Territory: 1 region(s). Executed: 2001-09-20",
      "execution_date": "2001-09-20",
      "effective_date": "2001-09-15",
      "expiration_date": null,
      "licensor": {
        "name": "POLLOCK REALTY CORPORATION",
        "address": "c/o TIG Real Estate Services, Inc. P. O. Box 802047 Dallas, Texas 75380-2047",
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": "PHONE: 972-661-0232; FAX: 972-661-0235"
      },
      "licensee": {
        "name": "Access Pharmaceuticals, Inc.",
        "address": "2600 N. Stemmons Freeway, Suite 164-176 Dallas, TX 75207-2107",
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": "PHONE: 214-905-5100; FAX: 214-905-5101"
      },
      "agreement_grants": "Modifies the original Lease Agreement to include Suites 162-176, totaling 14,468 net rentable square feet. Tenant's proportionate share of the Building is 36.41%.",
      "exclusivity_grant_type": null,
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [],
      "licensed_territory": [
        {
          "territory_name": "County of Dallas, City of Dallas and the State of Texas",
          "territory_type": null,
          "restrictions": null
        }
      ],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": 42000.0,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "LEASE AMENDMENT",
          "type": "EXHIBIT",
          "description": "SUPPLEMENTAL LEASE AGREEMENT",
          "reference_section": "EX-10.24 6 r10k-002.txt"
        }
      ],
      "governing_law": "State of Texas",
      "jurisdiction": "County of Dallas, City of Dallas",
      "termination_rights": "Not explicitly mentioned, but the agreement is subject to the receipt by Landlord of an executed Lease Agreement from Arena Pharmaceuticals, Inc.",
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2002/10-K/0000318306-02-000003/EX-10.24.txt",
      "year": "2002",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:58:26.627678",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2004/10-Q/0000318306-04-000016/EX-10.26.txt": {
    "contract": {
      "title": "LICENSE AND SUPPLY AGREEMENT (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between ACCESS PHARMACEUTICALS, INC. (licensor) and WYETH (licensee). Grant type: Exclusive. Licenses 1 product(s). Territory: 4 region(s). Executed: 2004-01-06",
      "execution_date": "2004-01-06",
      "effective_date": "2004-01-06",
      "expiration_date": null,
      "licensor": {
        "name": "ACCESS PHARMACEUTICALS, INC.",
        "address": "2600 Stemmons Freeway, Suite 176, Dallas, Texas 75207-2107",
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "WYETH",
        "address": "Five Giralda Farms, Madison, New Jersey 07940",
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "agreement_grants": "ACCESS grants to WYETH (a) the exclusive right and license in the Field under ACCESS's Intellectual Property Rights to market, offer for sale, sell and import products, including the Product, in the Territory, (b) the exclusive right and license in the Field under ACCESS's Intellectual Property Rights to use the Product in the Territory, provided that such right and license is limited to such use as is necessary for WYETH to market, offer for sale, sell, import and, subject to the terms and conditions set forth in Section 2.6, Manufacture the Product in the Territory, and (c) a non- exclusive right and license to use the Product and all information and Intellectual Property Rights with respect thereto (including, without limitation, data, studies and clinical trials) solely for the purpose of obtaining Regulatory Approval.",
      "exclusivity_grant_type": "Exclusive",
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": "the treatment of oral pain utilizing anesthetics (excluding the treatment of sore throat and excluding any product containing amlexanox as an active ingredient)",
      "licensed_patents": [],
      "licensed_products": [
        {
          "product_name": "Product",
          "description": "a proprietary oral mucoadhesive, erodible form of drug that contains *",
          "category": "pharmaceutical"
        }
      ],
      "licensed_territory": [
        {
          "territory_name": "United States",
          "territory_type": "country",
          "restrictions": null
        },
        {
          "territory_name": "Canada",
          "territory_type": "country",
          "restrictions": null
        },
        {
          "territory_name": "Mexico",
          "territory_type": "country",
          "restrictions": null
        },
        {
          "territory_name": "Puerto Rico",
          "territory_type": "territory",
          "restrictions": null
        }
      ],
      "contract_term": "variable end",
      "contract_term_details": "Term commences on the Effective Date and ends upon the expiration of the last-to-expire patent within the Patents in such country, except as and if sooner terminated in accordance with Section 8.",
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": true,
      "confidential_materials": "WYETH Confidential Information; ACCESS Confidential Information",
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "Exhibit A",
          "type": null,
          "description": "more fully described in Exhibit A attached hereto (the \"Product\")",
          "reference_section": "Recitals"
        },
        {
          "name": "Exhibit C",
          "type": null,
          "description": "Quality Agreement",
          "reference_section": "1.1.17"
        }
      ],
      "governing_law": null,
      "jurisdiction": null,
      "termination_rights": null,
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2004/10-Q/0000318306-04-000016/EX-10.26.txt",
      "year": "2004",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:58:31.368979",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2005/10-Q/0000318306-05-000009/EX-10.29.txt": {
    "contract": {
      "title": "SECURITIES PURCHASE AGREEMENT (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between ACCESS PHARMACEUTICALS, INC. (licensor) and Buyers (licensee). Grant type: Nonexclusive. Licenses 2 product(s). Upfront payment: $2,633,000.00. Executed: 2005-03-30",
      "execution_date": "2005-03-30",
      "effective_date": null,
      "expiration_date": null,
      "licensor": {
        "name": "ACCESS PHARMACEUTICALS, INC.",
        "address": "Delaware corporation",
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "Buyers",
        "address": "listed on Schedule I attached hereto",
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "agreement_grants": "the Company shall issue and sell to the Buyer(s), as provided herein, and the Buyer(s) shall purchase up to Two Million Six Hundred Thirty Three Thousand Dollars (2,633,000) of secured convertible debentures (the \"Convertible Debentures\"), which shall be convertible into shares of the Company's common stock, par value 0.01 (the \"Common Stock\")",
      "exclusivity_grant_type": "Nonexclusive",
      "exclusivity_milestones": [],
      "right_to_sublicense": false,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [
        {
          "product_name": "Convertible Debentures",
          "description": "secured convertible debentures",
          "category": "debentures"
        },
        {
          "product_name": "Common Stock",
          "description": "shares of the Company's common stock, par value 0.01",
          "category": "stock"
        }
      ],
      "licensed_territory": [],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": 2633000.0,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "Schedule I",
          "type": null,
          "description": "list of Buyers",
          "reference_section": null
        },
        {
          "name": "Exhibit A",
          "type": "agreement",
          "description": "Registration Rights Agreement",
          "reference_section": null
        },
        {
          "name": "Exhibit B",
          "type": "agreement",
          "description": "Escrow Agreement",
          "reference_section": null
        },
        {
          "name": "Exhibit C",
          "type": "agreement",
          "description": "Security Agreement",
          "reference_section": null
        },
        {
          "name": "Exhibit D",
          "type": "agreement",
          "description": "Pledge and Escrow Agreement",
          "reference_section": null
        },
        {
          "name": "Exhibit E",
          "type": "instructions",
          "description": "Irrevocable Transfer Agent Instructions",
          "reference_section": null
        }
      ],
      "governing_law": "U.S. Securities Act",
      "jurisdiction": null,
      "termination_rights": "Buyer may withdraw his Subscription Amount and terminate this Agreement as to such Buyer at any time after the execution hereof and prior to Closing",
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2005/10-Q/0000318306-05-000009/EX-10.29.txt",
      "year": "2005",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:58:38.429853",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2005/10-Q/0000318306-05-000009/EX-10.28.txt": {
    "contract": {
      "title": "Secured Debenture (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between Access Pharmaceuticals, Inc. (licensor) and Highgate House Funds, Ltd. (licensee). Grant type: Nonexclusive. Executed: 2006-03-30",
      "execution_date": "2006-03-30",
      "effective_date": "2006-03-30",
      "expiration_date": null,
      "licensor": {
        "name": "Access Pharmaceuticals, Inc.",
        "address": "Delaware corporation",
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "Highgate House Funds, Ltd.",
        "address": null,
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "agreement_grants": "The Company hereby promises to pay to the order of the Holder on the one year anniversary of the date hereof (\"Maturity Date\"), in lawful money of the United States of America and in immediately available funds the principal sum of One Million Three Hundred Sixteen Thousand Five Hundred Dollars ($1,316,500), together with interest on the unpaid principal of this Debenture at the rate of seven percent (7%) per year (compounded monthly) from the date of this Debenture until paid in full.",
      "exclusivity_grant_type": "Nonexclusive",
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [],
      "licensed_territory": [],
      "contract_term": "fixed end date",
      "contract_term_details": "One year anniversary of 2006-03-30",
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "Exhibit A",
          "type": null,
          "description": null,
          "reference_section": "Section 1.03"
        },
        {
          "name": "Exhibit A",
          "type": null,
          "description": null,
          "reference_section": "Section 1.09"
        }
      ],
      "governing_law": null,
      "jurisdiction": null,
      "termination_rights": null,
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2005/10-Q/0000318306-05-000009/EX-10.28.txt",
      "year": "2005",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:58:42.569013",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2005/10-Q/0000318306-05-000009/EX-10.27.txt": {
    "contract": {
      "title": "STANDBY EQUITY DISTRIBUTION AGREEMENT (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between ACCESS PHARMACEUTICALS, INC. (licensor) and CORNELL CAPITAL PARTNERS, LP (licensee). Grant type: Nonexclusive. Licenses 1 product(s). Territory: 1 region(s). Executed: 2005-03-30",
      "execution_date": "2005-03-30",
      "effective_date": null,
      "expiration_date": null,
      "licensor": {
        "name": "ACCESS PHARMACEUTICALS, INC.",
        "address": null,
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "CORNELL CAPITAL PARTNERS, LP",
        "address": null,
        "entity_type": "limited partnership",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "agreement_grants": "The Company shall issue and sell to the Investor, from time to time as provided herein, and the Investor shall purchase from the Company up to 15000000 of the Company's common stock, par value $0.01 per share",
      "exclusivity_grant_type": "Nonexclusive",
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [
        {
          "product_name": "Common Stock",
          "description": "Company's common stock, par value $0.01 per share",
          "category": null
        }
      ],
      "licensed_territory": [
        {
          "territory_name": "Worldwide",
          "territory_type": null,
          "restrictions": null
        }
      ],
      "contract_term": "variable end",
      "contract_term_details": "The period commencing on the earlier to occur of (i) the Effective Date, or (ii) such earlier date as the Company and the Investor may mutually agree in writing, and expiring on the earliest to occur of (x) the date on which the Investor shall have made payment of Advances pursuant to this Agreement in the aggregate amount of 15000000, (y) the date this Agreement is terminated pursuant to Section 2.4, or (z) the date occurring twenty-four (24) months after the Effective Date.",
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": 0.0,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": "non-transferable without agreement by licensor",
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [],
      "governing_law": "the laws of the State of Delaware",
      "jurisdiction": null,
      "termination_rights": null,
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2005/10-Q/0000318306-05-000009/EX-10.27.txt",
      "year": "2005",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:58:45.558708",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2005/10-Q/0000318306-05-000009/EX-10.30.txt": {
    "contract": {
      "title": "INVESTOR REGISTRATION RIGHTS AGREEMENT (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between ACCESS PHARMACEUTICALS, INC. (licensor) and Investors (licensee). Grant type: Nonexclusive. Licenses 1 product(s). Territory: 1 region(s). Executed: 2005-03-30",
      "execution_date": "2005-03-30",
      "effective_date": null,
      "expiration_date": null,
      "licensor": {
        "name": "ACCESS PHARMACEUTICALS, INC.",
        "address": "Delaware corporation",
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "Investors",
        "address": "listed on Schedule I attached hereto",
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "agreement_grants": "The Company has agreed to provide certain registration rights under the Securities Act of 1933, as amended, and the rules and regulations there under, or any similar successor statute (collectively, the \"Securities Act\"), and applicable state securities laws.",
      "exclusivity_grant_type": "Nonexclusive",
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [
        {
          "product_name": "Common Stock",
          "description": "shares of the Company's common stock, par value $0.01 per share",
          "category": null
        }
      ],
      "licensed_territory": [
        {
          "territory_name": "United States",
          "territory_type": null,
          "restrictions": null
        }
      ],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": "The Company shall prepare and file, no later than sixty (60) days from the date hereof (the \"Scheduled Filing Deadline\"), with the SEC a registration statement on Form S-1 or SB-2 (or, if the Company is then eligible, on Form S-3) under the Securities Act (the \"Initial Registration Statement\") for the resale by the Investors of the Registrable Securities, which includes at least six hundred fifty eight thousand two hundred fifty (658,250) shares of Common Stock to be issued upon conversion of the Convertible Debentures.",
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "Schedule I",
          "type": null,
          "description": "list of undersigned investors",
          "reference_section": null
        }
      ],
      "governing_law": null,
      "jurisdiction": null,
      "termination_rights": "In the event the Registration Statement is not filed by the Scheduled Filing Deadline or is not declared effective by the SEC on or before the Scheduled Effective Date, or if after the Registration Statement has been declared effective by the SEC, sales cannot be made pursuant to the Registration Statement (whether because of a failure to keep the Registration Statement effective, failure to disclose such information as is necessary for sales to be made pursuant to the Registration Statement, failure to register sufficient shares of Common Stock or otherwise then as partial relief for the damages to any holder of Registrable Securities by reason of any such delay in or reduction of its ability to sell the underlying shares of Common Stock (which remedy shall not be exclusive of any other remedies at law or in equity), subject to the obligations of the Investors pursuant to Section 4(b) hereof, the Company will pay as liquidated damages (the \"Liquidated Damages\") to the holder, at the holder's option, either a cash amount or shares of the Company's Common Stock within three (3) business days, after demand therefore, equal to two percent (1.5%) of the liquidated value of the Convertible Debentures outstanding as Liquidated Damages for each thirty (30) day period after the Scheduled Filing Deadline or the Scheduled Effective Date as the case may be.",
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2005/10-Q/0000318306-05-000009/EX-10.30.txt",
      "year": "2005",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:58:50.499484",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2006/10-Q_A/0000318306-06-000001/EX-10.29.txt": {
    "contract": {
      "title": "SECURED DEBENTURE ACCESS PHARMACEUTICALS, INC. (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between Access Pharmaceuticals, Inc. (licensor) and Highgate House Funds, Ltd. (licensee). Grant type: Nonexclusive. Executed: 2006-03-30",
      "execution_date": "2006-03-30",
      "effective_date": "2005-03-30",
      "expiration_date": null,
      "licensor": {
        "name": "Access Pharmaceuticals, Inc.",
        "address": "Delaware corporation",
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "Highgate House Funds, Ltd.",
        "address": null,
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "agreement_grants": "The Company hereby promises to pay to the order of the Holder on the one year anniversary of the date hereof (\"Maturity Date\"), in lawful money of the United States of America and in immediately available funds the principal sum of One Million Three Hundred Sixteen Thousand Five Hundred Dollars (1316500), together with interest on the unpaid principal of this Debenture at the rate of seven percent (7%) per year (compounded monthly) from the date of this Debenture until paid in full.",
      "exclusivity_grant_type": "Nonexclusive",
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [],
      "licensed_territory": [],
      "contract_term": "fixed end date",
      "contract_term_details": "one year anniversary of the date hereof",
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "Exhibit A",
          "type": null,
          "description": "Form of Conversion Notice",
          "reference_section": "Section 1.03"
        },
        {
          "name": "Exhibit A",
          "type": null,
          "description": "Assets and property of the Company",
          "reference_section": "Section 1.09"
        }
      ],
      "governing_law": null,
      "jurisdiction": null,
      "termination_rights": "Upon the occurrence of an Event of Default, the Holder may, in its sole discretion, accelerate full repayment of all debentures outstanding and accrued interest thereon or may, notwithstanding any limitations contained in this Debenture and/or the Securities Purchase Agreement, convert all debentures outstanding and accrued interest thereon into shares of Common Stock pursuant to Section 1.03 herein.",
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2006/10-Q_A/0000318306-06-000001/EX-10.29.txt",
      "year": "2006",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:58:54.597862",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2006/10-Q_A/0000318306-06-000001/EX-10.28.txt": {
    "contract": {
      "title": "SECURITIES PURCHASE AGREEMENT (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between ACCESS PHARMACEUTICALS, INC. (licensor) and Buyers (licensee). Executed: 2005-03-30",
      "execution_date": "2005-03-30",
      "effective_date": null,
      "expiration_date": null,
      "licensor": {
        "name": "ACCESS PHARMACEUTICALS, INC.",
        "address": null,
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "Buyers",
        "address": null,
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "agreement_grants": "The Company shall issue and sell to the Buyer(s), and the Buyer(s) shall purchase up to 2633000 of secured convertible debentures (the \"Convertible Debentures\"), which shall be convertible into shares of the Company's common stock, par value $0.01 (the \"Common Stock\")",
      "exclusivity_grant_type": null,
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [],
      "licensed_territory": [],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "Schedule I",
          "type": null,
          "description": "List of Buyers",
          "reference_section": null
        },
        {
          "name": "Exhibit A",
          "type": "Registration Rights Agreement",
          "description": "Investor Registration Rights Agreement",
          "reference_section": null
        },
        {
          "name": "Exhibit B",
          "type": "Escrow Agreement",
          "description": null,
          "reference_section": null
        },
        {
          "name": "Exhibit C",
          "type": "Security Agreement",
          "description": null,
          "reference_section": null
        },
        {
          "name": "Exhibit D",
          "type": "Pledge and Escrow Agreement",
          "description": null,
          "reference_section": null
        },
        {
          "name": "Exhibit E",
          "type": "Irrevocable Transfer Agent Instructions",
          "description": null,
          "reference_section": null
        }
      ],
      "governing_law": null,
      "jurisdiction": null,
      "termination_rights": null,
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2006/10-Q_A/0000318306-06-000001/EX-10.28.txt",
      "year": "2006",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:58:58.483784",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2006/10-Q_A/0000318306-06-000001/EX-10.32.txt": {
    "contract": {
      "title": "PLEDGE AND ESCROW AGREEMENT (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between ACCESS PHARMACEUTICALS, INC. (licensor) and CORNELL CAPITAL PARTNERS, LP; HIGHGATE HOUSE FUNDS, LTD. (licensee). Grant type: Nonexclusive. Executed: 2005-03-30",
      "execution_date": "2005-03-30",
      "effective_date": "2005-03-30",
      "expiration_date": null,
      "licensor": {
        "name": "ACCESS PHARMACEUTICALS, INC.",
        "address": "2600 Stemmons Freeway, Suite 176 Dallas, TX 75207",
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": "Attention: Kerry P. Gray Telephone: (214) 905-5100 Facsimile: (214) 905-5101"
      },
      "licensee": {
        "name": "CORNELL CAPITAL PARTNERS, LP; HIGHGATE HOUSE FUNDS, LTD.",
        "address": "101 Hudson Street, Suite 3700 Jersey City, NJ 07302",
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": "Attention: Mark A. Angelo Telephone: (201) 985-8300 Facsimile: (201) 985-8744"
      },
      "agreement_grants": "Pledgor grants to Pledgee a security interest in all Pledged Shares as security for Pledgor's obligations under the Convertible Debentures.",
      "exclusivity_grant_type": "Nonexclusive",
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [],
      "licensed_territory": [],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": false,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": false,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": false,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": true,
      "confidential_materials": "Terms of the agreement",
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [],
      "governing_law": "New Jersey",
      "jurisdiction": "state superior courts located in Hudson County, New Jersey or Federal district courts located in Newark, New Jersey",
      "termination_rights": "Upon full payment of all amounts due to the Pledgee under the Convertible Debentures, by repayment or conversion in accordance with the terms of the Convertible Debenture, this Agreement and Pledgee's security interest and rights in and to the Pledged Shares shall terminate.",
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2006/10-Q_A/0000318306-06-000001/EX-10.32.txt",
      "year": "2006",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:59:02.269299",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2006/10-Q_A/0000318306-06-000001/EX-10.33.txt": {
    "contract": {
      "title": "ESCROW AGREEMENT (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between ACCESS PHARMACEUTICALS, INC. (licensor) and Investor(s) (licensee). Grant type: Nonexclusive. Licenses 1 product(s). Upfront payment: $2,633,000.00. Executed: 2005-03-30",
      "execution_date": "2005-03-30",
      "effective_date": null,
      "expiration_date": null,
      "licensor": {
        "name": "ACCESS PHARMACEUTICALS, INC.",
        "address": "a Delaware corporation",
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "Investor(s)",
        "address": null,
        "entity_type": "Buyer(s) listed in the Securities Purchase Agreement",
        "jurisdiction": null,
        "contact_info": null
      },
      "agreement_grants": "Escrow Agent agrees to hold, invest and disburse the Escrow Funds in accordance with this Agreement.",
      "exclusivity_grant_type": "Nonexclusive",
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [
        {
          "product_name": "Convertible Debentures",
          "description": "secured convertible debentures which shall be convertible into the Company's Common Stock, par value $0.01 per share",
          "category": "Convertible Securities"
        }
      ],
      "licensed_territory": [],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": 2633000.0,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": "non-transferable without agreement by licensor",
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": true,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [],
      "governing_law": null,
      "jurisdiction": null,
      "termination_rights": "Escrow Agent may resign from the performance of its duties hereunder at any time by giving thirty (30) days' prior written notice to the parties or may be removed, with or without cause, by the parties, acting jointly, by furnishing a Joint Written Direction to Escrow Agent, at any time by the giving of ten (10) days' prior written notice to Escrow Agent as provided herein below.",
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2006/10-Q_A/0000318306-06-000001/EX-10.33.txt",
      "year": "2006",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:59:05.334916",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2006/10-Q_A/0000318306-06-000001/EX-10.27.txt": {
    "contract": {
      "title": "STANDBY EQUITY DISTRIBUTION AGREEMENT (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between ACCESS PHARMACEUTICALS, INC. (licensor) and CORNELL CAPITAL PARTNERS, LP (licensee). Grant type: Nonexclusive. Licenses 1 product(s). Territory: 1 region(s). Executed: 2005-03-30",
      "execution_date": "2005-03-30",
      "effective_date": null,
      "expiration_date": null,
      "licensor": {
        "name": "ACCESS PHARMACEUTICALS, INC.",
        "address": null,
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "CORNELL CAPITAL PARTNERS, LP",
        "address": null,
        "entity_type": "limited partnership",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "agreement_grants": "The Company shall issue and sell to the Investor, from time to time as provided herein, and the Investor shall purchase from the Company up to 15000000 of the Company's common stock, par value $0.01 per share",
      "exclusivity_grant_type": "Nonexclusive",
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [
        {
          "product_name": "Common Stock",
          "description": "Company's common stock, par value $0.01 per share.",
          "category": null
        }
      ],
      "licensed_territory": [
        {
          "territory_name": "Worldwide",
          "territory_type": null,
          "restrictions": null
        }
      ],
      "contract_term": "variable end",
      "contract_term_details": "The period commencing on the earlier to occur of (i) the Effective Date, or (ii) such earlier date as the Company and the Investor may mutually agree in writing, and expiring on the earliest to occur of (x) the date on which the Investor shall have made payment of Advances pursuant to this Agreement in the aggregate amount of 15000000, (y) the date this Agreement is terminated pursuant to Section 2.4, or (z) the date occurring twenty-four (24) months after the Effective Date.",
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [],
      "governing_law": null,
      "jurisdiction": null,
      "termination_rights": "The obligation of the Investor to make an Advance to the Company pursuant to this Agreement shall terminate permanently (including with respect to an Advance Date that has not yet occurred) in the event that (i) there shall occur any stop order or suspension of the effectiveness of the Registration Statement for an aggregate of seventy- five (75) Trading Days, other than due to the acts of the Investor, during the Commitment Period, and (ii) the Company shall at any time fail materially to comply with the requirements of Article VI and such failure is not cured within thirty (30) days after receipt of written notice from the Investor, provided, however, that this termination provision shall not apply to any period commencing upon the filing of a post-effective amendment to such Registration Statement and ending upon the date on which such post effective amendment is declared effective by the SEC.",
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2006/10-Q_A/0000318306-06-000001/EX-10.27.txt",
      "year": "2006",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:59:09.476585",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2006/10-Q_A/0000318306-06-000001/EX-10.31.txt": {
    "contract": {
      "title": "SECURITY AGREEMENT (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between ACCESS PHARMACEUTICALS, INC. (licensor) and BUYER(S) listed on Schedule I attached to the Securities Purchase Agreement dated the date hereof (licensee). Grant type: Nonexclusive. Executed: 2005-03-30",
      "execution_date": "2005-03-30",
      "effective_date": "2005-03-30",
      "expiration_date": null,
      "licensor": {
        "name": "ACCESS PHARMACEUTICALS, INC.",
        "address": null,
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "BUYER(S) listed on Schedule I attached to the Securities Purchase Agreement dated the date hereof",
        "address": null,
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "agreement_grants": "The Company hereby grants to the Secured Party a security interest in and to the pledged property identified on Exhibit A hereto (collectively referred to as the \"Pledged Property\"), subject to a security interest on certain specific equipment granted to Agilent Financial Services, Inc., until the satisfaction of the Obligations",
      "exclusivity_grant_type": "Nonexclusive",
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [],
      "licensed_territory": [],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": false,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "Schedule I",
          "type": null,
          "description": "List of Buyers attached to the Securities Purchase Agreement",
          "reference_section": null
        },
        {
          "name": "Exhibit A",
          "type": null,
          "description": "Pledged Property",
          "reference_section": "Section 2.1"
        }
      ],
      "governing_law": null,
      "jurisdiction": null,
      "termination_rights": null,
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2006/10-Q_A/0000318306-06-000001/EX-10.31.txt",
      "year": "2006",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:59:12.751269",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2006/10-Q_A/0000318306-06-000001/EX-10.30.txt": {
    "contract": {
      "title": "INVESTOR REGISTRATION RIGHTS AGREEMENT (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between ACCESS PHARMACEUTICALS, INC. (licensor) and Investors (licensee). Grant type: Nonexclusive. Licenses 1 product(s). Upfront payment: $2,633,000.00. Territory: 1 region(s). Executed: 2005-03-30",
      "execution_date": "2005-03-30",
      "effective_date": null,
      "expiration_date": null,
      "licensor": {
        "name": "ACCESS PHARMACEUTICALS, INC.",
        "address": "Delaware corporation",
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "Investors",
        "address": "listed on Schedule I attached hereto",
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "agreement_grants": "The Company has agreed to provide certain registration rights under the Securities Act of 1933, as amended, and the rules and regulations there under, or any similar successor statute (collectively, the \"Securities Act\"), and applicable state securities laws.",
      "exclusivity_grant_type": "Nonexclusive",
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [
        {
          "product_name": "shares of Common Stock",
          "description": "issuable to the Investors upon conversion of the Convertible Debentures pursuant to the Securities Purchase Agreement and the Buyer's Shares, as this term is defined in the Securities Purchase Agreement.",
          "category": null
        }
      ],
      "licensed_territory": [
        {
          "territory_name": "United States",
          "territory_type": null,
          "restrictions": null
        }
      ],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": "The Company shall prepare and file, no later than sixty (60) days from the date hereof (the \"Scheduled Filing Deadline\"), with the SEC a registration statement on Form S-1 or SB-2 (or, if the Company is then eligible, on Form S-3) under the Securities Act (the \"Initial Registration Statement\") for the resale by the Investors of the Registrable Securities, which includes at least six hundred fifty eight thousand two hundred fifty (658,250) shares of Common Stock to be issued upon conversion of the Convertible Debentures.",
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": 2633000.0,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "Schedule I",
          "type": null,
          "description": "list of undersigned investors",
          "reference_section": null
        }
      ],
      "governing_law": "Delaware",
      "jurisdiction": null,
      "termination_rights": "In the event the Registration Statement is not filed by the Scheduled Filing Deadline or is not declared effective by the SEC on or before the Scheduled Effective Date, or if after the Registration Statement has been declared effective by the SEC, sales cannot be made pursuant to the Registration Statement (whether because of a failure to keep the Registration Statement effective, failure to disclose such information as is necessary for sales to be made pursuant to the Registration Statement, failure to register sufficient shares of Common Stock or otherwise then as partial relief for the damages to any holder of Registrable Securities by reason of any such delay in or reduction of its ability to sell the underlying shares of Common Stock (which remedy shall not be exclusive of any other remedies at law or in equity), subject to the obligations of the Investors pursuant to Section 4(b) hereof, the Company will pay as liquidated damages (the \"Liquidated Damages\") to the holder, at the holder's option, either a cash amount or shares of the Company's Common Stock within three (3) business days, after demand therefore, equal to two percent (1.5%) of the liquidated value of the Convertible Debentures outstanding as Liquidated Damages for each thirty (30) day period after the Scheduled Filing Deadline or the Scheduled Effective Date as the case may be.",
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2006/10-Q_A/0000318306-06-000001/EX-10.30.txt",
      "year": "2006",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:59:18.109438",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2006/10-Q_A/0000318306-06-000001/EX-10.34.txt": {
    "contract": {
      "title": "REGISTRATION RIGHTS AGREEMENT (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between ACCESS PHARMACEUTICALS, INC. (licensor) and CORNELL CAPITAL PARTNERS, LP (licensee). Grant type: Nonexclusive. Licenses 1 product(s). Executed: 2005-03-30",
      "execution_date": "2005-03-30",
      "effective_date": null,
      "expiration_date": null,
      "licensor": {
        "name": "ACCESS PHARMACEUTICALS, INC.",
        "address": null,
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "CORNELL CAPITAL PARTNERS, LP",
        "address": null,
        "entity_type": "limited partnership",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "agreement_grants": "The Company has agreed to provide certain registration rights under the Securities Act of 1933, as amended, and the rules and regulations thereunder, or any similar successor statute (collectively, the \"Securities Act\"), and applicable state securities laws.",
      "exclusivity_grant_type": "Nonexclusive",
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [
        {
          "product_name": "Common Stock",
          "description": "shares of the Company's common stock, par value $0.01 per share",
          "category": "stock"
        }
      ],
      "licensed_territory": [],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": "The Company shall prepare and file with the SEC a Registration Statement on Form S-3, S-1, SB-2 or on such other form as is available. The Company shall cause such Registration Statement to be declared effective by the SEC prior to the first sale to the Investor of the Company's Common Stock pursuant to the Standby Equity Distribution Agreement.",
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": "non-transferable without agreement by licensor",
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [],
      "governing_law": "Delaware",
      "jurisdiction": null,
      "termination_rights": "The Company shall keep the Registration Statement effective pursuant to Rule 415 at all times until the date on which the Investor shall have sold all the Registrable Securities covered by such Registration Statement or until all shared covered by the Registration Statement may be sold pursuant to Rule 144(k) (the \"Registration Period\")",
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2006/10-Q_A/0000318306-06-000001/EX-10.34.txt",
      "year": "2006",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:59:21.792496",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2007/10-Q/0000318306-07-000060/10.43.html": {
    "contract": {
      "title": "AMENDMENT TO 7.0% (SUBJECT TO ADJUSTMENT) CONVERTIBLE PROMISSORY NOTES DUE OCTOBER 26, 2007 (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between ACCESS PHARMACEUTICALS, INC. (licensor) and Oracle Partners LP; Oracle Institutional Partners LP; SAM Oracle Investments Inc.; Oracle Offshore Ltd. (licensee). Executed: 2007-10-26",
      "execution_date": "2007-10-26",
      "effective_date": null,
      "expiration_date": null,
      "licensor": {
        "name": "ACCESS PHARMACEUTICALS, INC.",
        "address": null,
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "Oracle Partners LP; Oracle Institutional Partners LP; SAM Oracle Investments Inc.; Oracle Offshore Ltd.",
        "address": null,
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "agreement_grants": "Amending certain provisions of those certain 7.0% (Subject to Adjustment) Convertible Promissory Notes Due October 26, 2007 (each as amended and in effect from time to time, a \"Note\") from the Company to each Holder in the original principal amount of 2524500, 698500, 660000 and 132000, respectively.",
      "exclusivity_grant_type": null,
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [],
      "licensed_territory": [],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [],
      "governing_law": "the laws of the State of Texas",
      "jurisdiction": null,
      "termination_rights": "Not specified.",
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2007/10-Q/0000318306-07-000060/10.43.html",
      "year": "2007",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:59:24.761706",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2007/10-Q/0000318306-07-000060/10.44.html": {
    "contract": {
      "title": "AMENDMENT TO AMENDED AND RESTATED 7.5% SECURED CONVERTIBLE PROMISSORY NOTE DUE OCTOBER 25, 2007 (Unknown)",
      "contract_type": "License Agreement",
      "summary": "This is an amendment to a promissory note, changing the due date from October 25, 2007 to November 15, 2007.",
      "execution_date": "2007-10-25",
      "effective_date": null,
      "expiration_date": null,
      "licensor": {
        "name": "SCO Capital Partners LLC",
        "address": null,
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "licensee": {
        "name": "Access Pharmaceuticals, Inc.",
        "address": null,
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "agreement_grants": "Amends certain provisions of the Amended and Restated 7.5% Secured Convertible Promissory Note",
      "exclusivity_grant_type": null,
      "exclusivity_milestones": [],
      "right_to_sublicense": false,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [],
      "licensed_territory": [],
      "contract_term": "fixed end date",
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": true,
      "confidential_materials": "Terms and conditions of the Note",
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [],
      "governing_law": "laws of the State of New York",
      "jurisdiction": "laws of the State of New York",
      "termination_rights": "Not specified",
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2007/10-Q/0000318306-07-000060/10.44.html",
      "year": "2007",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:59:27.548647",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2008/S-1/0001140361-08-006400/10.27.html": {
    "contract": {
      "title": "AMENDED AND RESTATED PREFERRED STOCK AND WARRANT PURCHASE AGREEMENT (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between Access Pharmaceuticals, Inc. (licensor) and Purchasers (licensee). Grant type: Nonexclusive. Licenses 2 product(s). Executed: 2008-02-04",
      "execution_date": "2008-02-04",
      "effective_date": null,
      "expiration_date": null,
      "licensor": {
        "name": "Access Pharmaceuticals, Inc.",
        "address": null,
        "entity_type": "Delaware corporation",
        "jurisdiction": null,
        "contact_info": null
      },
      "licensee": {
        "name": "Purchasers",
        "address": "Schedule 1",
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "agreement_grants": "The Company desires to issue and sell to the Purchasers, and the Purchasers, severally and not jointly, desire to purchase from the Company, in the aggregate, (i) up to 4,000 shares of the Company's Series A Cumulative Convertible Preferred Stock, and (ii) Common Stock Purchase Warrants (the \"Warrants\") entitling the holders thereof to purchase up to 6,666,700 shares of the Company's Common Stock as more fully set forth herein.",
      "exclusivity_grant_type": "Nonexclusive",
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [
        {
          "product_name": "Series A Cumulative Convertible Preferred Stock",
          "description": null,
          "category": null
        },
        {
          "product_name": "Common Stock Purchase Warrants",
          "description": null,
          "category": null
        }
      ],
      "licensed_territory": [],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "Schedule 1",
          "type": null,
          "description": "Purchasers",
          "reference_section": null
        },
        {
          "name": "Exhibit A",
          "type": "form",
          "description": "Investor Rights Agreement",
          "reference_section": null
        },
        {
          "name": "Exhibit B",
          "type": "form",
          "description": "Certificate of Designation",
          "reference_section": null
        },
        {
          "name": "Exhibit C",
          "type": "form",
          "description": "Common Stock Purchase Warrant",
          "reference_section": null
        },
        {
          "name": "Exhibit D",
          "type": "form",
          "description": "Placement Agent Warrants",
          "reference_section": null
        },
        {
          "name": "Exhibit G",
          "type": "form",
          "description": "Series A Certificate of Amendment",
          "reference_section": null
        },
        {
          "name": "Exhibit H",
          "type": "form",
          "description": "Warrants to be issued in Additional Closings",
          "reference_section": null
        }
      ],
      "governing_law": null,
      "jurisdiction": null,
      "termination_rights": null,
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2008/S-1/0001140361-08-006400/10.27.html",
      "year": "2008",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:59:31.354207",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2008/S-1/0001140361-08-006400/10.23.html": {
    "contract": {
      "title": "PREFERRED STOCK AND WARRANT PURCHASE AGREEMENT (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between Access Pharmaceuticals, Inc. (licensor) and Purchasers (licensee). Grant type: Nonexclusive. Licenses 2 product(s). Upfront payment: $10,015,000.00. Executed: 2007-11-07",
      "execution_date": "2007-11-07",
      "effective_date": null,
      "expiration_date": null,
      "licensor": {
        "name": "Access Pharmaceuticals, Inc.",
        "address": null,
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "Purchasers",
        "address": null,
        "entity_type": "parties named herein on Schedule 1",
        "jurisdiction": null,
        "contact_info": null
      },
      "agreement_grants": "The Company desires to issue and sell to the Purchasers, and the Purchasers, severally and not jointly, desire to purchase from the Company, in the aggregate, (i) up to 3,227.3617 shares of the Company's Series A Cumulative Convertible Preferred Stock, and (ii) Common Stock Purchase Warrants (the \"Warrants\") entitling the holders thereof to purchase up to 3,440,882 shares of the Company's Common Stock as more fully set forth herein.",
      "exclusivity_grant_type": "Nonexclusive",
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [
        {
          "product_name": "Series A Cumulative Convertible Preferred Stock",
          "description": "up to 3227.3617 shares",
          "category": null
        },
        {
          "product_name": "Common Stock Purchase Warrants",
          "description": "entitling the holders thereof to purchase up to 3,440,882 shares of the Company's Common Stock",
          "category": null
        }
      ],
      "licensed_territory": [],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": 10015000.0,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "Schedule 1",
          "type": null,
          "description": "Purchasers",
          "reference_section": null
        },
        {
          "name": "Exhibit A",
          "type": null,
          "description": "Investor Rights Agreement",
          "reference_section": null
        },
        {
          "name": "Exhibit B",
          "type": "Certificate of Designation",
          "description": "Certificate of Designations of Rights and Preferences of Series A Convertible Preferred Stock",
          "reference_section": "1.2"
        },
        {
          "name": "Exhibit C",
          "type": null,
          "description": "Common Stock Purchase Warrant",
          "reference_section": null
        },
        {
          "name": "Exhibit D",
          "type": null,
          "description": "Placement Agent Warrants",
          "reference_section": null
        },
        {
          "name": "Exhibit E",
          "type": null,
          "description": "Closing Escrow Agreement",
          "reference_section": null
        }
      ],
      "governing_law": "laws of the State of Texas",
      "jurisdiction": null,
      "termination_rights": "Not applicable",
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2008/S-1/0001140361-08-006400/10.23.html",
      "year": "2008",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:59:35.143198",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2008/S-1/0001140361-08-006400/10.24.html": {
    "contract": {
      "title": "INVESTOR RIGHTS AGREEMENT (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between Access Pharmaceuticals, Inc. (licensor) and Purchasers (licensee). Executed: 2007-11-10",
      "execution_date": "2007-11-10",
      "effective_date": null,
      "expiration_date": null,
      "licensor": {
        "name": "Access Pharmaceuticals, Inc.",
        "address": null,
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "Purchasers",
        "address": null,
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "agreement_grants": "Agreement grants rights related to the Preferred Stock and Warrant Purchase Agreement, dated as of 2007-11-07, including rights related to registration of shares of Common Stock issuable upon conversion of the Preferred Stock and Warrants.",
      "exclusivity_grant_type": null,
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [],
      "licensed_territory": [],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "Schedule 1",
          "type": null,
          "description": "List of Purchasers executing the Agreement",
          "reference_section": null
        }
      ],
      "governing_law": null,
      "jurisdiction": null,
      "termination_rights": null,
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2008/S-1/0001140361-08-006400/10.24.html",
      "year": "2008",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:59:38.776274",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2008/S-1/0001140361-08-006400/10.28.html": {
    "contract": {
      "title": "Amended and Restated Investor Rights Agreement (Unknown)",
      "contract_type": "Investor Rights Agreement",
      "summary": "This is an Amended and Restated Investor Rights Agreement made as of 2008-02-04, between Access Pharmaceuticals, Inc. and the Purchasers listed on Schedule 1. It amends and restates the Original Investor Rights Agreement dated 2007-11-10, in connection with the amendment and restatement of the Original Purchase Agreement dated 2007-11-07.",
      "execution_date": "2008-02-04",
      "effective_date": null,
      "expiration_date": null,
      "licensor": {
        "name": "Access Pharmaceuticals, Inc.",
        "address": null,
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "Purchasers",
        "address": "listed on Schedule 1",
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "agreement_grants": "The Company and the Purchasers hereby amend and restate the Original Investor Rights Agreement as set forth below.",
      "exclusivity_grant_type": "Nonexclusive",
      "exclusivity_milestones": [],
      "right_to_sublicense": false,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": false,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [
        {
          "product_name": "Common Stock",
          "description": "Company's Common Stock, par value $0.01 per share.",
          "category": null
        },
        {
          "product_name": "Preferred Stock",
          "description": "Company's Series A Cumulative Convertible Preferred Stock, par value $0.01 per share.",
          "category": null
        },
        {
          "product_name": "Warrants",
          "description": "Common Stock purchase warrants issued pursuant to the Purchase Agreement",
          "category": null
        }
      ],
      "licensed_territory": [
        {
          "territory_name": "Worldwide",
          "territory_type": null,
          "restrictions": null
        }
      ],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": false,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": 0.0,
      "stacking_clause_indicator": false,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": false,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": "non-transferable without agreement by licensor",
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": true,
      "confidential_materials": "Information not otherwise defined but subject to confidentiality includes information related to the Purchasers and the terms of the agreement.",
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "Schedule 1",
          "type": null,
          "description": "List of Purchasers",
          "reference_section": "Parties"
        }
      ],
      "governing_law": "Not specified",
      "jurisdiction": "Not specified",
      "termination_rights": "Not specified",
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2008/S-1/0001140361-08-006400/10.28.html",
      "year": "2008",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:59:43.034713",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2008/10-Q/0000318306-08-000027/10.30.html": {
    "contract": {
      "title": "AMENDMENT TO EMPLOYMENT AGREEMENT (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between Access Pharmaceuticals, Inc. (licensor) and Jeffrey B. Davis (licensee). Executed: 2008-04-09",
      "execution_date": "2008-04-09",
      "effective_date": "2008-04-09",
      "expiration_date": null,
      "licensor": {
        "name": "Access Pharmaceuticals, Inc.",
        "address": null,
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "Jeffrey B. Davis",
        "address": null,
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "agreement_grants": "Amends the original Employment Agreement dated 2008-01-04. Section 1 is amended to correct the date to 2008-01-04. Section 2 is amended to specify the Executive's time commitment. Section 3(a) is amended to change the salary from 335000 to 240000. Section 3(c) is deleted. Section 4 is amended regarding 'Discharge for Cause'. Section 4 is amended to change 'Discharge Other Than For Cause' to 'Same as for Discharge For Cause'.",
      "exclusivity_grant_type": null,
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [],
      "licensed_territory": [],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "AMENDMENT TO DAVIS EMPLOYMENT AGREEMENT",
          "type": "EX-10.30",
          "description": "Unassociated Document",
          "reference_section": null
        }
      ],
      "governing_law": null,
      "jurisdiction": null,
      "termination_rights": null,
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2008/10-Q/0000318306-08-000027/10.30.html",
      "year": "2008",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:59:45.662177",
    "mtime": 1750965720.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2010/S-1_A/0000318306-10-000002/10.29.html": {
    "contract": {
      "title": "Securities Purchase Agreement (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between Access Pharmaceuticals, Inc. (licensor) and Purchaser (licensee). Grant type: Nonexclusive. Licenses 2 product(s). Territory: 1 region(s). Executed: 2010-01-01",
      "execution_date": "2010-01-01",
      "effective_date": null,
      "expiration_date": null,
      "licensor": {
        "name": "Access Pharmaceuticals, Inc.",
        "address": "Delaware corporation",
        "entity_type": null,
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "Purchaser",
        "address": null,
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "agreement_grants": "The Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.",
      "exclusivity_grant_type": "Nonexclusive",
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [
        {
          "product_name": "Shares of Common Stock",
          "description": null,
          "category": null
        },
        {
          "product_name": "Warrants",
          "description": null,
          "category": null
        }
      ],
      "licensed_territory": [
        {
          "territory_name": "United States",
          "territory_type": null,
          "restrictions": null
        }
      ],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": "Bingham McCutchen LLP; Weinstein Smith LLP",
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "EXHIBIT 10.29",
          "type": "SECURITIES PURCHASE AGREEMENT",
          "description": null,
          "reference_section": null
        },
        {
          "name": "Exhibit A",
          "type": null,
          "description": "form of Warrants",
          "reference_section": "Warrants"
        },
        {
          "name": "Exhibit B",
          "type": null,
          "description": "legal opinion of Company Counsel",
          "reference_section": "2.2(a)(ii)"
        }
      ],
      "governing_law": null,
      "jurisdiction": null,
      "termination_rights": null,
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2010/S-1_A/0000318306-10-000002/10.29.html",
      "year": "2010",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:59:48.750522",
    "mtime": 1750965780.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2010/S-1_A/0000318306-10-000007/10.29.html": {
    "contract": {
      "title": "Securities Purchase Agreement (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between Access Pharmaceuticals, Inc. (licensor) and Purchaser (licensee). Grant type: Nonexclusive. Licenses 3 product(s). Territory: 1 region(s). Executed: 2010-01-01",
      "execution_date": "2010-01-01",
      "effective_date": null,
      "expiration_date": null,
      "licensor": {
        "name": "Access Pharmaceuticals, Inc.",
        "address": "Delaware corporation",
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "Purchaser",
        "address": null,
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "agreement_grants": "The Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.",
      "exclusivity_grant_type": "Nonexclusive",
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [
        {
          "product_name": "Shares of Common Stock",
          "description": "shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.",
          "category": null
        },
        {
          "product_name": "Warrants",
          "description": "Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a) hereof, which Warrants shall be exercisable commencing on _____ and have a term of exercise equal to ____ years from the date of Closing, in the form of Exhibit A attached hereto.",
          "category": null
        },
        {
          "product_name": "Warrant Shares",
          "description": "shares of Common Stock issuable upon exercise of the Warrants.",
          "category": null
        }
      ],
      "licensed_territory": [
        {
          "territory_name": "United States",
          "territory_type": null,
          "restrictions": null
        }
      ],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "Exhibit A",
          "type": "form",
          "description": "form of Warrants",
          "reference_section": "Warrants"
        },
        {
          "name": "Exhibit B",
          "type": "legal opinion",
          "description": "legal opinion of Company Counsel",
          "reference_section": "2.2(a)(ii)"
        }
      ],
      "governing_law": null,
      "jurisdiction": null,
      "termination_rights": null,
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2010/S-1_A/0000318306-10-000007/10.29.html",
      "year": "2010",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:59:52.137298",
    "mtime": 1750965780.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2010/10-K/0000318306-10-000018/10.9.html": {
    "contract": {
      "title": "Amendment to Rights Agreement (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between Access Pharmaceuticals, Inc. (licensor) and American Stock Transfer & Trust Company (licensee). Licenses 1 product(s). Executed: 2007-11-09",
      "execution_date": "2007-11-09",
      "effective_date": null,
      "expiration_date": null,
      "licensor": {
        "name": "Access Pharmaceuticals, Inc.",
        "address": "a Delaware corporation",
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "American Stock Transfer & Trust Company",
        "address": "a New York corporation",
        "entity_type": "corporation",
        "jurisdiction": "New York",
        "contact_info": null
      },
      "agreement_grants": "Amending certain provisions of the Rights Agreement, dated as of 2001-10-31",
      "exclusivity_grant_type": null,
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": "Rights associated with Common Shares",
      "licensed_patents": [],
      "licensed_products": [
        {
          "product_name": "Common Shares",
          "description": "Shares of the Company",
          "category": null
        }
      ],
      "licensed_territory": [],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "EXHIBIT 10.9",
          "type": null,
          "description": "AMENDMENT TO RIGHTS AGREEMENT",
          "reference_section": null
        }
      ],
      "governing_law": "the laws of the State of Delaware",
      "jurisdiction": null,
      "termination_rights": "Not specified in this amendment.",
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": "Amendment to the definition of \"Acquiring Person\" in Section 1(a) of the Agreement; Amendment to Section 3(a) of the Agreement; Insertion of a new Section 3(d) regarding Convertible Preferred Stock; Amendment to the second paragraph of Exhibit C of the Agreement.",
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2010/10-K/0000318306-10-000018/10.9.html",
      "year": "2010",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T15:59:57.213688",
    "mtime": 1750965780.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2010/8-K/0000318306-10-000080/10.1.html": {
    "contract": {
      "title": "SECURITIES PURCHASE AGREEMENT (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between Access Pharmaceuticals, Inc. (licensor) and Purchaser (licensee). Grant type: Nonexclusive. Licenses 3 product(s). Upfront payment: $8,000,000.00. Territory: 1 region(s). Executed: 2010-12-09",
      "execution_date": "2010-12-09",
      "effective_date": null,
      "expiration_date": null,
      "licensor": {
        "name": "Access Pharmaceuticals, Inc.",
        "address": "Delaware corporation",
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "Purchaser",
        "address": null,
        "entity_type": "corporation",
        "jurisdiction": null,
        "contact_info": null
      },
      "agreement_grants": "The Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.",
      "exclusivity_grant_type": "Nonexclusive",
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [
        {
          "product_name": "Shares",
          "description": "shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.",
          "category": null
        },
        {
          "product_name": "Warrants",
          "description": "Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a) hereof, which Warrants shall be exercisable commencing on the Closing Date and have a term of exercise equal to five (5) years from the date of Closing, in the form of Exhibit A attached hereto.",
          "category": null
        },
        {
          "product_name": "Warrant Shares",
          "description": "shares of Common Stock issuable upon exercise of the Warrants.",
          "category": null
        }
      ],
      "licensed_territory": [
        {
          "territory_name": "United States",
          "territory_type": null,
          "restrictions": "The principal Trading Market is open for trading. Trading Market means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE AMEX, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange or the OTC Bulletin Board (or any successors to any of the foregoing)."
        }
      ],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": 8000000.0,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "Exhibit A",
          "type": null,
          "description": "form of Warrants",
          "reference_section": "Warrants"
        },
        {
          "name": "Exhibit B",
          "type": null,
          "description": "legal opinion of Company Counsel",
          "reference_section": "2.2(a)(ii)"
        }
      ],
      "governing_law": "laws of the State of New York",
      "jurisdiction": "State of New York",
      "termination_rights": "Not specified in the provided text.",
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2010/8-K/0000318306-10-000080/10.1.html",
      "year": "2010",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T16:00:01.480246",
    "mtime": 1750965780.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2011/8-K/0000318306-11-000023/10.1.html": {
    "contract": {
      "title": "SECURITIES PURCHASE AGREEMENT (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between Access Pharmaceuticals, Inc. (licensor) and Investors (licensee). Executed: 2011-11-01",
      "execution_date": "2011-11-01",
      "effective_date": null,
      "expiration_date": null,
      "licensor": {
        "name": "Access Pharmaceuticals, Inc.",
        "address": "2600 Stemmons Freeway, Suite 176, Dallas, Texas 75207",
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "Investors",
        "address": null,
        "entity_type": "investors",
        "jurisdiction": null,
        "contact_info": null
      },
      "agreement_grants": "The Company shall issue and sell to each Investor, and each Investor shall, severally and not jointly, purchase from the Company, the number of Common Shares, 2.5 Year Warrants exercisable for the number of 2.5 Year Warrant Shares and 5 Year Warrants exercisable for the number of 5 Year Warrant Shares set forth opposite such Investor's name on Exhibit A hereto under the headings \"Common Shares,\" \"2.5 Year Warrant Shares\" and \"5 Year Warrant Shares,\" respectively, for the price set forth opposite such Investor's name on Exhibit A hereto under the heading \"Purchase Price\".",
      "exclusivity_grant_type": null,
      "exclusivity_milestones": [],
      "right_to_sublicense": false,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [],
      "licensed_territory": [],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "Schedule of Investors",
          "type": "Exhibit",
          "description": null,
          "reference_section": "Exhibit A"
        },
        {
          "name": "2.5 Year Warrants",
          "type": "Exhibit",
          "description": null,
          "reference_section": "Exhibit F-1"
        },
        {
          "name": "5 Year Warrants",
          "type": "Exhibit",
          "description": null,
          "reference_section": "Exhibit F-2"
        },
        {
          "name": "Irrevocable Transfer Agent Instructions",
          "type": "Exhibit",
          "description": null,
          "reference_section": "Exhibit E"
        }
      ],
      "governing_law": null,
      "jurisdiction": null,
      "termination_rights": null,
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2011/8-K/0000318306-11-000023/10.1.html",
      "year": "2011",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T16:00:04.874025",
    "mtime": 1750965780.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2014/8-K/0000318306-14-000027/10.30.html": {
    "contract": {
      "title": "LICENSE AGREEMENT (Unknown)",
      "contract_type": "License Agreement",
      "summary": "This is a license agreement between Access Pharmaceuticals, Inc. and Plasma Technologies, LLC, granting Access Pharmaceuticals an exclusive, royalty-bearing license to use and commercialize Plasma Technologies' licensed technology in the specified territory.",
      "execution_date": null,
      "effective_date": "2014-09-19",
      "expiration_date": null,
      "licensor": {
        "name": "Plasma Technologies, LLC",
        "address": "36 Prioleau Street, Unit N, Charleston, SC 29401",
        "entity_type": "limited liability corporation",
        "jurisdiction": "South Carolina",
        "contact_info": null
      },
      "licensee": {
        "name": "Access Pharmaceuticals, Inc.",
        "address": "1325 Avenue of the Americas, 27th Floor, New York, NY USA",
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "agreement_grants": "PLASMATECH grants to ACCESS an exclusive, nontransferable (except as set forth in Section 8.1), royalty-bearing license, with the right to grant sublicenses only as set forth below, (i) to use and practice the Licensed Technology and (ii) to make, have made, use, offer for sale, sell and import Licensed Products in the Territory.",
      "exclusivity_grant_type": "Exclusive",
      "exclusivity_milestones": [],
      "right_to_sublicense": true,
      "sublicense_restrictions": [
        {
          "restriction_type": "Written Agreement",
          "description": "Each sublicense shall be in writing and shall include provisions acknowledging that such sublicense is subject to the applicable license(s) granted hereunder.",
          "conditions": null
        },
        {
          "restriction_type": "Obligations",
          "description": "Requiring each Sublicensee to perform all applicable obligations of ACCESS hereunder in the applicable portion of the Territory (specifically including the obligation to make reports and keep and maintain records of Net Sales to at least the same extent as required of ACCESS under this Agreement).",
          "conditions": null
        },
        {
          "restriction_type": "Access and Audit Rights",
          "description": "Allowing PLASMATECH the same access and audit rights with respect to such records as permitted with respect to ACCESS' records hereunder.",
          "conditions": null
        },
        {
          "restriction_type": "No Further Sublicensing",
          "description": "Prohibiting further sublicensing by the Sublicensee.",
          "conditions": null
        },
        {
          "restriction_type": "Copy of Sublicense",
          "description": "ACCESS shall provide an un-redacted copy of each sublicense it enters into to PLASMATECH promptly following execution.",
          "conditions": null
        }
      ],
      "crosslicensing_indicator": false,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [],
      "licensed_territory": [
        {
          "territory_name": "Territory",
          "territory_type": null,
          "restrictions": null
        }
      ],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": true,
      "retained_licensor_rights": "Title to the Licensed Technology and any other intellectual property rights of PLASMATECH shall at all times remain vested in PLASMATECH. Except for the limited license granted in Section 2.1(a), no other rights are granted, no other use is permitted, and all other rights are expressly reserved.",
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": "PLASMATECH will, upon ACCESS' reasonable request at any time within two (2) years following the Effective Date, transfer any PLASMATECH Know-How to ACCESS that has not been previously delivered to ACCESS by a means mutually agreed between the parties. After two (2) years following the Effective Date, PLASMATECH will have no further obligation to disclose or transfer to ACCESS any PLASMATECH Know-How.",
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": 5000000.0,
      "stacking_clause_indicator": false,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": false,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": "non-transferable without agreement by licensor",
      "assignment_restrictions_details": "except as set forth in Section 8.1",
      "insurance_clause_indicator": null,
      "audit_clause": "ACCESS shall keep complete and accurate records in sufficient detail to enable the royalties and Sublicense Income percentage payable hereunder to be determined for a period of at least three (3) years from the date of each payment.",
      "late_delivery_clauses": null,
      "diligence_clause": [
        {
          "requirement_type": "Development and Commercialization",
          "description": "ACCESS shall use Commercially Reasonable Efforts to Develop and Commercialize Licensed Products throughout the Territory during the Term.",
          "timeline": null,
          "consequences": "The Parties acknowledge and agree that the foregoing shall be a material obligation of ACCESS within the meaning of Section 5.2(a)."
        },
        {
          "requirement_type": "Development Plan",
          "description": "ACCESS shall provide PLASMATECH with a detailed written plan for the Development of Licensed Products (the \"Development Plan\") within ninety (90) days after the Effective Date.",
          "timeline": null,
          "consequences": null
        },
        {
          "requirement_type": "Quarterly Reports",
          "description": "ACCESS shall provide PLASMATECH with quarterly reports relating to the Development of Licensed Products and shall provide PLASMATECH with an updated Development Plan on an annual basis.",
          "timeline": null,
          "consequences": null
        },
        {
          "requirement_type": "Commercialization Plan",
          "description": "Within sixty (60) days after Commercialization Regulatory Approval of a Licensed Product in any country within the Territory, ACCESS shall provide PLASMATECH with detailed written plans for Commercialization of the Licensed Product (the \"Commercialization Plan\").",
          "timeline": null,
          "consequences": null
        },
        {
          "requirement_type": "Commercialization Plan Updates",
          "description": "ACCESS shall provide PLASMATECH updates to the Commercialization Plan on a quarterly basis, and in writing no less than annually.",
          "timeline": null,
          "consequences": null
        }
      ],
      "confidential_agreement": true,
      "confidential_materials": "Material that has been omitted and for which confidential treatment has been requested.",
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "SCHEDULE A",
          "type": null,
          "description": null,
          "reference_section": "1.1"
        }
      ],
      "governing_law": null,
      "jurisdiction": null,
      "termination_rights": null,
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2014/8-K/0000318306-14-000027/10.30.html",
      "year": "2014",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T16:00:14.145314",
    "mtime": 1750965780.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2014/8-K/0000318306-14-000027/10.31.html": {
    "contract": {
      "title": "Employment Letter Agreement (Unknown)",
      "contract_type": "Employment Agreement",
      "summary": "This is an employment agreement between Access Pharmaceuticals, Inc. and Scott Schorer for the position of Chief Executive Officer.",
      "execution_date": "2014-09-19",
      "effective_date": "2014-09-19",
      "expiration_date": null,
      "licensor": {
        "name": "Access Pharmaceuticals, Inc.",
        "address": "1325 Avenue of the Americas, 27th Floor New York, New York 10019",
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "licensee": {
        "name": "Scott Schorer",
        "address": "33 Anchorage Lane Duxbury, MA 02332",
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "agreement_grants": "Employment as Chief Executive Officer with attendant responsibilities and perquisites.",
      "exclusivity_grant_type": null,
      "exclusivity_milestones": [],
      "right_to_sublicense": false,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [],
      "licensed_territory": [],
      "contract_term": "variable end",
      "contract_term_details": "The agreement is effective as of the date above, and cash compensation and fringe benefits will accrue until the closing of the planned equity offering.",
      "contract_releases": null,
      "non_compete_covenant_indicator": false,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": false,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": false,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": true,
      "confidential_materials": "Proprietary Information includes all clinical and laboratory data and derivatives thereof, clinical and scientific documents, protocols, investigator's brochures, data collection tools, study reports, product formulations, product designs and functions, programs, manuals, tradenames, trademarks, service marks or other material registered or otherwise protected or protectable under state, federal, or foreign patent, trademark, copyright, or similar laws; all trade or business secrets of the Company and any technical, scientific, or business materials that are treated by the Company as confidential, including, but not limited to, information concerning: customer or vendor lists, salaries and fees paid by the Company, general business operations, ideas, discoveries, costs, profits, sales, marketing strategies, distribution procedures, methods of doing business, servicing clients, customer relations, business forms developed by or for the Company, proposals and contracts, documentation and drawings, all whether in writing, oral or machine-readable form, software programs, however embodied, diagnostic techniques, and information obtained by or given to the Company about or belonging to its customers, potential customers or others.",
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [],
      "governing_law": null,
      "jurisdiction": null,
      "termination_rights": null,
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2014/8-K/0000318306-14-000027/10.31.html",
      "year": "2014",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T16:00:17.840455",
    "mtime": 1750965780.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2014/8-K/0000318306-14-000027/10.32.html": {
    "contract": {
      "title": "Employment Letter Agreement (Unknown)",
      "contract_type": "Employment Agreement",
      "summary": "License agreement between Access Pharmaceuticals, Inc. (licensor) and Harrison G. Wehner, III (licensee). Executed: 2014-09-19",
      "execution_date": "2014-09-19",
      "effective_date": "2014-09-19",
      "expiration_date": null,
      "licensor": {
        "name": "Access Pharmaceuticals, Inc.",
        "address": "1325 Avenue of the Americas, 27th Floor New York, New York 10019",
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "licensee": {
        "name": "Harrison G. Wehner, III",
        "address": "322 King Caesar Road Duxbury, MA 02332",
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "agreement_grants": "Offer of employment as President and Chief Financial Officer with attendant responsibilities and perquisites.",
      "exclusivity_grant_type": null,
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [],
      "licensed_territory": [],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": true,
      "confidential_materials": "All clinical and laboratory data and derivatives thereof, clinical and scientific documents, protocols, investigator's brochures, data collection tools, study reports, product formulations, product designs and functions, programs, manuals, tradenames, trademarks, service marks or other material registered or otherwise protected or protectable under state, federal, or foreign patent, trademark, copyright, or similar laws; all trade or business secrets of the Company and any technical, scientific, or business materials that are treated by the Company as confidential, including, but not limited to, information concerning: customer or vendor lists, salaries and fees paid by the Company, general business operations, ideas, discoveries, costs, profits, sales, marketing strategies, distribution procedures, methods of doing business, servicing clients, customer relations, business forms developed by or for the Company, proposals and contracts, documentation and drawings, all whether in writing, oral or machine-readable form, software programs, however embodied, diagnostic techniques, and information obtained by or given to the Company about or belonging to its customers, potential customers or others.",
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "EMPLOYMNET LETTER AGREEMENT HARRISON WEHNER",
          "type": "Employment Agreement",
          "description": "Employment agreement for Harrison Wehner",
          "reference_section": null
        }
      ],
      "governing_law": null,
      "jurisdiction": null,
      "termination_rights": null,
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2014/8-K/0000318306-14-000027/10.32.html",
      "year": "2014",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T16:00:21.493569",
    "mtime": 1750965780.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2015/10-Q_A/0001144204-15-049914/10.5.html": {
    "contract": {
      "title": "Securities Purchase Agreement (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between PlasmaTech Biopharmaceuticals, Inc. (licensor) and Purchaser (licensee). Grant type: Nonexclusive. Territory: 1 region(s). Executed: 2015-05-06",
      "execution_date": "2015-05-06",
      "effective_date": null,
      "expiration_date": null,
      "licensor": {
        "name": "PlasmaTech Biopharmaceuticals, Inc.",
        "address": "Delaware corporation",
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "Purchaser",
        "address": null,
        "entity_type": "purchaser",
        "jurisdiction": null,
        "contact_info": null
      },
      "agreement_grants": "The Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.",
      "exclusivity_grant_type": "Nonexclusive",
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [],
      "licensed_territory": [
        {
          "territory_name": "United States",
          "territory_type": null,
          "restrictions": null
        }
      ],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "Exhibit A",
          "type": null,
          "description": "Registration Rights Agreement",
          "reference_section": "Registration Rights Agreement"
        },
        {
          "name": "Exhibit B",
          "type": null,
          "description": "Legal opinion of Company Counsel",
          "reference_section": "2.2(a)(ii)"
        },
        {
          "name": "Exhibit C",
          "type": null,
          "description": "Common Stock purchase warrants",
          "reference_section": "Warrants"
        }
      ],
      "governing_law": "the laws of the State of New York",
      "jurisdiction": null,
      "termination_rights": null,
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2015/10-Q_A/0001144204-15-049914/10.5.html",
      "year": "2015",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T16:00:24.279712",
    "mtime": 1750965780.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2015/10-K/0001144204-15-020126/10.29.html": {
    "contract": {
      "title": "AMENDMENT TO LICENSE AGREEMENT (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between Plasma Technologies, LLC (licensor) and PlasmaTech Biopharmaceuticals, Inc. (licensee). Upfront payment: $5,000,000.00. Executed: 2015-01-23",
      "execution_date": "2015-01-23",
      "effective_date": null,
      "expiration_date": null,
      "licensor": {
        "name": "Plasma Technologies, LLC",
        "address": "c/o Eugene J. Zurlo, 36 Prioleau Street, Unit N, Charleston, SC 29401",
        "entity_type": "limited liability company",
        "jurisdiction": "South Carolina",
        "contact_info": null
      },
      "licensee": {
        "name": "PlasmaTech Biopharmaceuticals, Inc.",
        "address": "1325 Avenue of the Americas, 27th Floor, New York, NY USA",
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "agreement_grants": "rights and licenses granted by PLASMATECH",
      "exclusivity_grant_type": null,
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [],
      "licensed_territory": [],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": 5000000.0,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "EXHIBIT 10.29",
          "type": "EXHIBIT",
          "description": null,
          "reference_section": null
        }
      ],
      "governing_law": null,
      "jurisdiction": null,
      "termination_rights": null,
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2015/10-K/0001144204-15-020126/10.29.html",
      "year": "2015",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T16:00:26.530945",
    "mtime": 1750965780.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2019/10-Q/0001493152-19-016905/10.4.html": {
    "contract": {
      "title": "First Amendment to License Agreement (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between REGENXBIO Inc. (licensor) and Abeona Therapeutics Inc. (licensee). Upfront payment: $21,000,000.00. Executed: 2019-11-01",
      "execution_date": "2019-11-01",
      "effective_date": "2019-11-04",
      "expiration_date": null,
      "licensor": {
        "name": "REGENXBIO Inc.",
        "address": "9600 Blackwell Road, Suite 210, Rockville, MD 20850",
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "Abeona Therapeutics Inc.",
        "address": "1330 Avenue of the Americas, 33rd Floor, New York, NY 10019",
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "agreement_grants": "In partial consideration of the rights and licenses granted to Licensee under this Agreement, Licensee shall pay Licensor an initial fee of $21,000,000.",
      "exclusivity_grant_type": null,
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [],
      "licensed_territory": [],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": 21000000.0,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [],
      "governing_law": "Not specified",
      "jurisdiction": "Not specified",
      "termination_rights": "Initial fee shall be immediately payable upon termination of this Agreement or a Change of Control.",
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2019/10-Q/0001493152-19-016905/10.4.html",
      "year": "2019",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T16:00:28.786785",
    "mtime": 1750965780.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2019/10-K/0001144204-19-014623/10.18.html": {
    "contract": {
      "title": "License Agreement (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between REGENXBIO Inc. (licensor) and Abeona Therapeutics Inc. (licensee). Grant type: Exclusive. Licenses 1 patent(s). Licenses 1 product(s). Executed: 2009-03-06",
      "execution_date": "2009-03-06",
      "effective_date": "2018-11-04",
      "expiration_date": null,
      "licensor": {
        "name": "REGENXBIO Inc.",
        "address": "9600 Blackwell Road, Suite 210, Rockville, MD 20850",
        "entity_type": "corporation",
        "jurisdiction": "State of Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "Abeona Therapeutics Inc.",
        "address": "1330 Avenue of the Americas, 33rd Floor, New York, NY 10019",
        "entity_type": "corporation",
        "jurisdiction": "State of Delaware",
        "contact_info": null
      },
      "agreement_grants": "Licensor grants to Licensee an exclusive license under the Licensed Patents under the terms set forth in the agreement.",
      "exclusivity_grant_type": "Exclusive",
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": "CLN1 Field; CLN3 Field; MPS IIIA Field; MPS IIIB Field",
      "licensed_patents": [
        {
          "patent_number": "Exhibit A",
          "patent_title": null,
          "filing_date": null,
          "issue_date": null
        }
      ],
      "licensed_products": [
        {
          "product_name": "AAV9 product",
          "description": "any AAV9 product that is made, made for, used, sold, offered for sale, or imported by Licensee, its Affiliates, and any of its or their Sublicensees",
          "category": null
        }
      ],
      "licensed_territory": [],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": true,
      "confidential_materials": "all technical information, inventions, developments, discoveries, software, know-how, methods, techniques, formulae, animate and inanimate materials, data, processes, finances, business operations or affairs, and other proprietary ideas, whether or not patentable or copyrightable, of either Party that are (a) marked or otherwise identified as confidential or proprietary at the time of disclosure in writing; or (b) if disclosed orally, visually, or in another non-written form, identified as confidential at the time of disclosure and summarized in reasonable detail in writing as to its general content within 30 days after original disclosure; the terms and conditions of this Agreement and (ii) the records and reports referred to in Section 3.6; information provided to Licensee pursuant to the provisions of Section 7.1",
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "Exhibit 10.18",
          "type": "License Agreement",
          "description": null,
          "reference_section": null
        }
      ],
      "governing_law": null,
      "jurisdiction": null,
      "termination_rights": null,
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2019/10-K/0001144204-19-014623/10.18.html",
      "year": "2019",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T16:00:33.244964",
    "mtime": 1750965780.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2022/10-Q/0001493152-22-021969/10.3.html": {
    "contract": {
      "title": "LICENSE AGREEMENT BETWEEN ULTRAGENYX PHARMACEUTICAL INC. AND ABEONA THERAPEUTICS INC. (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between Abeona Therapeutics Inc. (licensor) and Ultragenyx Pharmaceutical Inc. (licensee). Licenses 1 product(s). Territory: 1 region(s). Executed: 2022-12-31",
      "execution_date": "2022-12-31",
      "effective_date": "2022-05-16",
      "expiration_date": null,
      "licensor": {
        "name": "Abeona Therapeutics Inc.",
        "address": "1330 Avenue of the Americas, 33rd Fl, New York, New York 10019, United States",
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "Ultragenyx Pharmaceutical Inc.",
        "address": "60 Leveroni Court, Novato, California 94949, United States",
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "agreement_grants": "Ultragenyx wishes to obtain from Abeona and Abeona wishes to grant to Ultragenyx certain rights and licenses under certain Patents, Know-How, and other intellectual property rights Controlled by Abeona to Develop, Manufacture, and Commercialize ABO-102 and associated Licensed Products in the Territory, subject to the terms and conditions set forth herein.",
      "exclusivity_grant_type": null,
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": "treatment of MPS IIIA",
      "licensed_patents": [],
      "licensed_products": [
        {
          "product_name": "ABO-102",
          "description": "proprietary AAV gene therapy for the treatment of MPS IIIA",
          "category": null
        }
      ],
      "licensed_territory": [
        {
          "territory_name": "Territory",
          "territory_type": null,
          "restrictions": null
        }
      ],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": true,
      "confidential_materials": "all trade secrets or confidential or proprietary information (including any tangible materials embodying any of the foregoing) of the disclosing Party or its Affiliates provided or disclosed to the other Party or any of its Affiliates in connection with this Agreement; \"Confidential Information\" (as defined in the Prior CDA) that was disclosed by a Party or any of its Affiliates to the other Party or any of its Affiliates under the Prior CDA; the terms and conditions of this Agreement",
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "Schedule 1.42",
          "type": "Schedule",
          "description": "Existing Vendor Agreements",
          "reference_section": null
        },
        {
          "name": "Schedule 1.72",
          "type": "Schedule",
          "description": "Licensed Patents",
          "reference_section": null
        },
        {
          "name": "Schedule 3.1.2",
          "type": "Schedule",
          "description": "Transition Plan",
          "reference_section": null
        },
        {
          "name": "Schedule 3.1.4",
          "type": "Schedule",
          "description": "Transition Costs",
          "reference_section": null
        },
        {
          "name": "Schedule 3.3",
          "type": "Schedule",
          "description": "Initial Transfer of Licensed Know-How",
          "reference_section": null
        },
        {
          "name": "Schedule 4.1.3",
          "type": "Schedule",
          "description": "Prior Development Costs",
          "reference_section": null
        },
        {
          "name": "Schedule 8.2",
          "type": "Schedule",
          "description": "Press Release",
          "reference_section": null
        },
        {
          "name": "Schedule 9.2.5",
          "type": "Schedule",
          "description": "Absence of Litigation",
          "reference_section": null
        }
      ],
      "governing_law": null,
      "jurisdiction": null,
      "termination_rights": null,
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2022/10-Q/0001493152-22-021969/10.3.html",
      "year": "2022",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T16:00:38.107080",
    "mtime": 1750965780.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2022/10-K/0001493152-22-008259/10.14.html": {
    "contract": {
      "title": "SETTLEMENT AGREEMENT AND MUTUAL RELEASE (Unknown)",
      "contract_type": "Settlement Agreement",
      "summary": "License agreement between REGENXBIO Inc. (licensor) and Abeona Therapeutics Inc. (licensee). Upfront payment: $30,000,000.00. Executed: 2018-11-04",
      "execution_date": "2018-11-04",
      "effective_date": null,
      "expiration_date": null,
      "licensor": {
        "name": "REGENXBIO Inc.",
        "address": null,
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "licensee": {
        "name": "Abeona Therapeutics Inc.",
        "address": null,
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "agreement_grants": "REGENXBIO licensed certain adeno-associated virus serotype 9 (\"AAV9\") technology to Abeona for the exclusive use in four specific fields: (a) treatment of Neuronal Ceroid Lipofuscinosis-1 (\"CLN1\"); (b) treatment of Neuronal Ceroid Lipofuscinosis-3 (\"CLN3\"); (c) treatment of Mucopolysaccharidosis type IIIA (\"MPS IIIA\"); and (d) treatment of Mucopolysaccharidosis type IIIB (\"MPS IIIB\");\n\nThis Settlement Agreement will not include a license of any kind from REGENXBIO to Abeona, and any future license between the Parties would have to be negotiated separately and require additional consideration than the consideration set forth in this Settlement Agreement.",
      "exclusivity_grant_type": null,
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": "treatment of Neuronal Ceroid Lipofuscinosis-1 (\"CLN1\"); treatment of Neuronal Ceroid Lipofuscinosis-3 (\"CLN3\"); treatment of Mucopolysaccharidosis type IIIA (\"MPS IIIA\"); and treatment of Mucopolysaccharidosis type IIIB (\"MPS IIIB\")",
      "licensed_patents": [],
      "licensed_products": [],
      "licensed_territory": [],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": 30000000.0,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "EXHIBIT 10.14",
          "type": null,
          "description": null,
          "reference_section": null
        }
      ],
      "governing_law": null,
      "jurisdiction": null,
      "termination_rights": null,
      "dispute_resolution": "In the event of any controversy or claim arising out of or relating to this Settlement Agreement, the Parties shall first attempt to resolve such controversy or claim through good faith negotiations for a period of not less than [****] following notification of such controversy or claim to the other Party. If such controversy or claim cannot be resolved by means of such negotiations during such period, then such controversy or claim shall be resolved by binding arbitration administered by the American Arbitration Association (\"AAA\") in accordance with the Commercial Arbitration Rules of the AAA in effect on the date of commencement of the arbitration, subject to the provisions of this Section 6. The arbitration shall be conducted as follows: (a) The arbitration shall be conducted by three arbitrators and shall be conducted in English and held in New York, New York. (b) In its demand for arbitration, the Party initiating the arbitration shall provide a statement setting forth the nature of the dispute, the names and addresses of all other parties, an estimate of the amount involved (if any), the remedy sought, otherwise specifying the issue to be resolved, and appointing one neutral arbitrator. In an answering statement to be filed by the responding Party within [****] after confirmation of the notice of filing of the demand is sent by the AAA, the responding Party shall appoint one neutral arbitrator. Within [****] from the date on which the responding Party appoints its neutral arbitrator, the first two arbitrators shall appoint a chairperson.",
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2022/10-K/0001493152-22-008259/10.14.html",
      "year": "2022",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T16:00:43.102430",
    "mtime": 1750965780.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2022/8-K/0001493152-22-011829/10.1.html": {
    "contract": {
      "title": "Securities Purchase Agreement (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between Abeona Therapeutics Inc. (licensor) and Purchaser (licensee). Grant type: Nonexclusive. Executed: 2022-04-29",
      "execution_date": "2022-04-29",
      "effective_date": null,
      "expiration_date": null,
      "licensor": {
        "name": "Abeona Therapeutics Inc.",
        "address": "Delaware",
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "Purchaser",
        "address": null,
        "entity_type": null,
        "jurisdiction": null,
        "contact_info": null
      },
      "agreement_grants": "The Company wishes to sell and issue to the Purchasers, upon the terms and subject to the conditions stated in this Agreement, shares of the Company's preferred stock, par value $0.01 per share, that are convertible into shares of the Company's common stock, $0.01 par value per share",
      "exclusivity_grant_type": "Nonexclusive",
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [],
      "licensed_territory": [],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "Exhibit A",
          "type": "form",
          "description": "Registration Rights Agreement",
          "reference_section": "Recitals"
        }
      ],
      "governing_law": null,
      "jurisdiction": null,
      "termination_rights": null,
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2022/8-K/0001493152-22-011829/10.1.html",
      "year": "2022",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T16:00:46.404284",
    "mtime": 1750965780.0
  },
  "../data/ABEONA-THERAPEUTICS-INC/2023/8-K/0001493152-23-023235/10.1.html": {
    "contract": {
      "title": "Securities Purchase Agreement (Unknown)",
      "contract_type": "License Agreement",
      "summary": "License agreement between Abeona Therapeutics Inc. (licensor) and Purchasers (licensee). Grant type: Nonexclusive. Licenses 3 product(s). Territory: 1 region(s). Executed: 2023-07-03",
      "execution_date": "2023-07-03",
      "effective_date": null,
      "expiration_date": null,
      "licensor": {
        "name": "Abeona Therapeutics Inc.",
        "address": "Delaware corporation",
        "entity_type": "corporation",
        "jurisdiction": "Delaware",
        "contact_info": null
      },
      "licensee": {
        "name": "Purchasers",
        "address": null,
        "entity_type": "purchasers",
        "jurisdiction": null,
        "contact_info": null
      },
      "agreement_grants": "The Company desires to issue and sell to the several Purchasers, and the several Purchasers desire to purchase from the Company, securities of the Company as more fully described in this Agreement.",
      "exclusivity_grant_type": "Nonexclusive",
      "exclusivity_milestones": [],
      "right_to_sublicense": null,
      "sublicense_restrictions": [],
      "crosslicensing_indicator": null,
      "licensed_field_of_use": null,
      "licensed_patents": [],
      "licensed_products": [
        {
          "product_name": "Shares",
          "description": "shares of Common Stock issued or issuable to the Purchasers pursuant to this Agreement.",
          "category": null
        },
        {
          "product_name": "Pre-Funded Warrants",
          "description": "Pre-Funded Warrants to Purchase Common Stock delivered to the Purchasers at the Closing in accordance with Section 2.2(a) hereof, in the form attached hereto as Exhibit A.",
          "category": null
        },
        {
          "product_name": "Warrant Shares",
          "description": "shares of Common Stock issuable upon exercise of the Pre-Funded Warrants.",
          "category": null
        }
      ],
      "licensed_territory": [
        {
          "territory_name": "United States",
          "territory_type": null,
          "restrictions": null
        }
      ],
      "contract_term": null,
      "contract_term_details": null,
      "contract_releases": null,
      "non_compete_covenant_indicator": null,
      "retained_licensor_rights": null,
      "product_branding_rights": null,
      "oem_type": null,
      "license_use_restrictions": null,
      "licensor_obligations": null,
      "licensor_improvements_clause": null,
      "licensee_improvements_clause": null,
      "licensee_right_to_improvements": null,
      "related_parties_licensor": null,
      "related_parties_licensee": null,
      "related_parties_unknown": null,
      "upfront_payment": null,
      "stacking_clause_indicator": null,
      "stacking_clause_terms": null,
      "most_favored_nations_clause": null,
      "licensee_infringement_indemnities": null,
      "licensor_product_liability_indemnities": null,
      "licensee_product_liability_indemnities": null,
      "delivery_supply": null,
      "relationship_between_contract_parties_clause": null,
      "warranties_litigation": null,
      "warranties_infringement": null,
      "warranties_ip_sufficiency": null,
      "warranties_product_or_service": null,
      "assignment_restrictions": null,
      "assignment_restrictions_details": null,
      "insurance_clause_indicator": null,
      "audit_clause": null,
      "late_delivery_clauses": null,
      "diligence_clause": [],
      "confidential_agreement": null,
      "confidential_materials": null,
      "patent_prosecution_responsibilities": null,
      "suspected_infringement_clause": null,
      "legal_representative_organization": null,
      "legal_representative_lawyer": null,
      "list_of_exhibits_and_attachments_in_contract": [
        {
          "name": "Exhibit A",
          "type": null,
          "description": "Pre-Funded Warrants to Purchase Common Stock",
          "reference_section": "Section 2.2(a)"
        },
        {
          "name": "Exhibit B",
          "type": null,
          "description": "Lock-Up Agreement",
          "reference_section": "Section 1.1"
        }
      ],
      "governing_law": "Law",
      "jurisdiction": null,
      "termination_rights": "Termination rights",
      "dispute_resolution": null,
      "risk_factors": [],
      "material_changes": null,
      "regulatory_requirements": null,
      "export_control": null
    },
    "metadata": {
      "file_path": "../data/ABEONA-THERAPEUTICS-INC/2023/8-K/0001493152-23-023235/10.1.html",
      "year": "2023",
      "filing_type": "Unknown",
      "accession": "Unknown",
      "exhibit": "Unknown"
    },
    "processed_at": "2025-07-16T16:00:49.785643",
    "mtime": 1750965780.0
  }
}